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STATISTICAL ANALYSES TO DETECT AND REFINE GENETIC ASSOCIATIONS 
WITH NEURODEGENERATIVE DISEASES 
 
Dementia is a clinical state caused by neurodegeneration and characterized by a 
loss of function in cognitive domains and behavior. Alzheimer’s disease (AD) is the most 
common form of dementia. Although the amyloid β (Aβ) protein and 
hyperphosphorylated tau aggregates in the brain are considered to be the key pathological 
hallmarks of AD, the exact cause of AD is yet to be identified. In addition, clinical 
diagnoses of AD can be error prone. Many previous studies have compared the clinical 
diagnosis of AD against the gold standard of autopsy confirmation and shown substantial 
AD misdiagnosis Hippocampal sclerosis of aging (HS-Aging) is one type of dementia 
that is often clinically misdiagnosed as AD. AD and HS-Aging are controlled by different 
genetic architectures. Familial AD, which often occurs early in life, is linked to mainly 
mutations in three genes: APP, PSEN1, and PSEN2. Late-onset AD (LOAD) is strongly 
associated with the ε4 allele of apolipoprotein E (APOE) gene. In addition to the APOE 
gene, genome-wide association studies (GWAS) have identified several single nucleotide 
polymorphisms (SNPs) in or close to some genes associated with LOAD. On the other 
hand, GRN, TMEM106B, ABCC9, and KCNMB2 have been reported to harbor risk alleles 
associated with HS-Aging pathology. Although GWAS have succeeded in revealing 
numerous susceptibility variants for dementias, it is an ongoing challenge to identify 
functional loci and to understand how they contribute to dementia pathogenesis. 
 
Until recently, rare variants were not investigated comprehensively. GWAS rely 
on genotype imputation which is not reliable for rare variants. Therefore, imputed rare 
variants are typically removed from GWAS analysis. Recent advances in sequencing 
technologies enable accurate genotyping of rare variants, thus potentially improving our 
understanding the role of rare variants on disease. There are significant computational 
and statistical challenges for these sequencing studies. Traditional single variant-based 
association tests are underpowered to detect rare variant associations. Instead, more 
powerful and computationally efficient approaches for aggregating the effects of rare 
variants have become a standard approach for association testing. The sequence-kernel 
association test (SKAT) is one of the most powerful rare variant analysis methods. A 
recently-proposed scan-statistic-based test is another approach to detect the location of 
rare variant clusters influencing disease. 
 
In the first study, we examined the gene-based associations of the four putative 
risk genes, GRN, TMEM106B, ABCC9, and KCNMB2 with HS-aging pathology. We 
analyzed haplotype associations of a targeted ABCC9 region with HS-Aging pathology 
and with ABCC9 gene expression. In the second study, we elucidated the role of the non-
coding SNPs identified in the International Genomics of Alzheimer’s Project (IGAP) 
consortium GWAS within a systems genetics framework to understand the flow of 
biological information underlying AD. In the last study, we identified genetic regions 
which contain rare variants associated with AD using a scan-statistic-based approach. 
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 Region-based Associations, Rare Variant Associations,  
 Systems Genetics 
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CHAPTER ONE 
Introduction 
Dementia is a clinical state caused by neurodegeneration and characterized by a loss of 
function in cognitive domains and undesirable changes in behavior. Alzheimer’s disease 
(AD) is the most common form of dementia, accounting for over 50% of dementia cases 
[1]. In the US, it has been estimated that 5.2 million people have AD and total payments 
from health-care and long-care services for AD patients are $214 billion in 2014 [2]. AD 
imposes a sever burden on patients themselves as well as caregivers and public health 
systems. Although it has been more than 100 years since Alois Alzheimer published 
“About a Peculiar Disease of the Cerebral Cortex” in 1907 [3], the exact cause of AD is 
yet to be identified. Amyloid β (Aβ) protein and hyperphosphorylated tau aggregates in 
the brain are considered to be the key pathological hallmarks in AD patients [4, 5]. A 
predominant mechanistic hypothesis for AD pathogenesis is the “amyloid cascade 
hypothesis” that suggests that AD is caused by lack of Aβ clearance, which triggers 
downstream neuronal injury such as synaptic and neuronal loss, enhanced 
neuroinflammation, tau hyperphosphorylation, and eventually the clinical symptoms of 
AD [6]. 
 
Aβ is a peptide of amino acids which is derived from amyloid precursor protein (APP) 
cleaved by β- and γ-secretases [7, 8]. The γ-secretase cleavage occurs at position 40 or 42 
of APP, yielding two major species of Aβ: Aβ40 (Aβ ending at residue 40) and Aβ42 (Aβ 
ending at residue 42) peptides [7]. Although Aβ40 is the most abundant form of Aβ, Aβ42 
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is less soluble and more neurotoxic than Aβ40 as it produces higher levels of Aβ 
oligomers [9, 10].  
 
In brains with AD, tau, a major neuronal microtubule-assembly-activator protein, is 
abnormally hyperphosphorylated in neurofibrillary tangles (NFTs). The function of tau is 
regulated by its degree of phosphorylation. Putatively, 85 phosphorylation sites have 
been identified at serine, threonine, and tyrosine residues [11, 12] with approximately 45 
specific sites identified for AD pathogenesis [13]. The abnormally hyperphosphorylated 
tau reduces the binding affinity to microtubules, binds to normal tau to form insoluble 
oligomers, and eventually develop NFTs which cause neurodegenerative diseases (called 
tauopathy) [14].  
 
HS-Aging 
The clinical diagnosis of AD is a challenging process that requires to remove other 
potential types of dementia. Many previous studies have compared the clinical diagnosis 
of AD against the gold standard of autopsy confirmation and shown substantial AD 
misdiagnosis [15-18]. The accurate diagnosis of AD is crucial to provide optimal 
treatments for patients as well as to recruit participants in clinical trials for new therapies. 
Hippocampal sclerosis of aging (HS-Aging) is one type of dementia that is often 
clinically misdiagnosed as AD [19-21]. Clinical signs and symptoms of HS-Aging are 
similar to those of AD with amnestic memory deficits [20, 21]. AD is characterized by 
the accumulation of amyloid plaques and neurofibrillary tangles [22], while HS-Aging is 
pathologically characterized by neuronal cell loss and gliosis in the hippocampus 
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unilaterally (~50%) or bilaterally [20, 23]. HS-Aging is generally diagnosed postmortem. 
The large majority of cases with HS-Aging show bilateral TAR DNA-binding protein 43 
(TDP-43) pathology in limbic structures [24, 25]. TDP-43 pathology had been considered 
to be a specific maker for frontotemporal lobar degeneration with ubiquitinated 
inclusions (FTLD-U). However, TDP-43 pathology is found in both HS-Aging and AD; 
in one study TDP-43 was detected in 71% of HS-Aging and 23% of AD cases [24]. There 
is no known treatment or preventive care for HS-Aging so far. Understanding its genetic 
architecture is important to reduce misdiagnosis with AD and to elucidate the aetiology 
of HS-Aging, yielding new insights into the molecular-based mechanisms of the 
underlying developmental process. 
 
Brief history of genetic risks of AD and HS-Aging 
Familial AD, which often occurs early in life, is linked mainly to mutations in three 
genes: APP and the presenilin proteins (PSEN1 and PSEN2) [8], which generally cause a 
shift in Aβ production from Aβ40 to less soluble and more neurotoxic Aβ42 (e.g., Volga 
German mutation in PSEN2 and Iberian mutation in APP) [26-29], an increased total Aβ 
levels (Swedish mutation in APP) [30], and an increased protofibril formation of Aβ 
(Arctic mutation in APP) [31]. On the other hand, late-onset AD (LOAD), which often 
occurs later in life and accounts for 95% of all AD cases [32], has more complex genetic 
architecture. The ε4 allele of apolipoprotein E (APOE) gene is the major genetic risk 
factor for LOAD. There are three apoE isoforms, apoE2 (cys112, cys158), apoE3 
(cys112, arg158), and apoE4 (arg112, arg158), determined by rs429358 (T/C) and rs7412 
(C/T) located on chromosome 19q13 (Table 1.1). The risk of AD is increased in 
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individuals with the ε4 allele: 2 to 3 times in those with one ε4 allele, and more than 12-
time in those with two ε4 alleles, whereas the ε2 allele has a protective effect: 0.6 times 
the odds compared to ε3/ ε3 carriers. These isoforms have different effects on Aβ 
metabolism, influencing age of onset of Aβ deposition. It is suggested that the binding 
ability of the apoE isoforms to Aβ follows the order of apoE2, apoE3, and apoE4, and 
therefore apoE2 and apoE3 inhibit the aggregation and enhance the clearance of Aβ 
compared to apoE4 [33]. The APOE alleles is also reported to be associated with tau 
levels in CSF [34, 35]. This association, however, has not been established as thoroughly 
as the association between APOE alleles and Aβ deposition [36].  
 
The microtubule-associated protein tau (MAPT) gene on chromosome 17q21, encoding 
tau and containing 16 exons, is also a candidate gene playing an important role in AD 
development. The tau primary transcript contains 13 exons without exons 4A, 6 and 8 in 
human brain. Exons 2, 3, and 10 are alternatively spliced, resulting in six different tau 
isoforms with the range from 352 to 441 amino acids. These isoforms differ by the 
presence of 0, 1, or 2 N-terminal inserts (0N = exons 2-3-; 1N = exons 2+3-; 2N = exons 
2+3+) and either three (3R) of four (4R) microtubule binding repeats located at the C 
terminus [37]. In the normal brain, the levels of 3R-tau and 4R-tau are approximately 
equal. The mutations in MAPT alter the balance by increasing the ratio of 4R to 3R, and 
disruption of the normal 4R to 3R ratio is associated with neurodegeneration by 
accelerating phosphorylation of tau. However, the ratio is approximately 1 in the AD 
brain with NFTs, and no mutations in MAPT have been found to be associated with AD 
so far. Instead, the MAPT haplotypes associated with AD have been found. Two 
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haplotypes exist in MAPT, directly oriented H1 and the inverted H2, which cover the 
entire MAPT gene. These haplotypes are tagged by a 238bp H1 insertion/H2 deletion 
polymorphism in intron 9 (del-In9). Many researchers reported that the H1 haplotype was 
associated with risk of LOAD [38-40]. Since the H1 and H2 haplotypes do not alter 
amino acid sequence, this pathogenic effect of the H1 haplotype may be due to 
differences in the gene expression rather than tau protein structure [38]. 
 
In addition to the APOE alleles and MAPT haplotypes, a series of genome-wide 
association studies (GWAS) have identified AD-associated single nucleotide 
polymorphisms (SNPs) in or close to genes that include CR1, BIN1, INPP5D, MEF2C, 
CD2AP, NME8, EPHA1, PTK2B, PICALM, SORL1, FERMT2, SLC24A4-RIN3, DSG2, 
CASS4, HLA-DRB5-DBR1, CLU, MS4A6A, ABCA7, CD33, ZCWPW1, and CELF1 
(Table 1.2) [41-45]. The report with the largest numbers of cases and controls was the 
International Genomics of Alzheimer’s Project (IGAP), a consortium to discover the 
genetic landscape of AD that included 74,046 individuals to show significant AD-
associations with 19 SNPs by meta-analyzing GWAS from four component consortia 
[41]. Although GWAS have succeeded in revealing numerous susceptibility SNPs for 
AD, it is an ongoing challenge to identify functional loci and to understand how they 
contribute to dementia pathogenesis. 
 
Unlike AD, the APOE ε4 allele is not a genetic risk factor for HS-Aging [19, 21, 25, 46, 
47]. The following four genes (in the chronological order they were so identified) have 
been reported to harbor risk alleles associated with HS-Aging pathology: GRN on 
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chromosome 17q, TMEM106B on chromosome 7p, ABCC9 on chromosome 12p, and 
KCNMB2 on chromosome 3q [21, 48-53]. The T-alleles of GRN rs5848 and TMEM106B 
rs1990622 were shown to have a risk of HS-Aging using an allele test, following the 
known relationship of those two genes to frontotemporal lobar degeneration with TDP-43 
inclusions (FTLD-TDP). The connections of the ABCC9 and KCNMB2 genes to HS-
Aging risk were discovered via GWAS. The association of ABCC9 SNP rs704180 with 
HS-Aging pathology was demonstrated using a recessive mode of inheritance (MOI) 
[51]. Beecham and colleagues reported the KCNMB2 SNP rs9637454 as the top SNP for 
HS pathology [48]. 
 
Genetic variants are located with much less frequency in coding regions than in non-
coding regions (about only 1% are within a protein-coding sequence) [54]. However, it is 
estimated that about 85% of the mutations with large effects on diseases are located in 
protein-coding functional regions [55]. To understand disease development mechanisms 
that underlie disease-associated genetic variants, identifying functional genes and/or 
variants is an important challenge. Functional variants may be located in 
nonsynonymous/synonymous coding regions, alternative splice region, and regulatory 
regions such as promoter, operator, insulator, enhancer and silencer. A nonsynonymous 
substitution includes a missense and nonsense mutations. The former alters the amino 
acid sequence of a protein, and the later introduces a premature termination codon 
resulting in a truncated protein. Many Mendelian diseases are due to nonsynonymous 
mutations causing deleterious amino acid substitutions. Synonymous mutation occurs in 
the coding region, but it does not change the amino acid sequence. These variants were 
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referred to as “silent mutation” until recently [56]. However, several synonymous 
mutations have been reported to affect mRNA splicing and stability, gene expression, and 
protein folding and function [56]. Other disease-associated genetic variants are located in 
the intronic and intergenic regions (i.e., non-coding regions) which may contain the 
regulatory or splice sites. They may have an important role in regulating expression level 
of disease-associated genes and modulating translation efficiency and stability [57].  
 
As shown in Table 1.2, all 21 variants identified in IGAP are non-coding. To elucidate 
the role of these SNPs, we hypothesized that each of the SNPs is: (1) a proxy of a coding 
variant or (2) a regulatory variant. One frequently used approach for the first hypothesis 
is to search coding variants in strong linkage disequilibrium (LD) with the variant 
identified by GWAS. LD is generally measured using the squared correlation coefficient 
(r2) between two variants, and the most widely used threshold is r2 ≥ 0.8. For the second 
hypothesis, expression quantitative trait locus (eQTL) analysis can be used. eQTL is a 
genetic locus that contributes to variation in gene expression. By mapping eQTL, we 
could investigate how the SNPs regulate gene expression.  
 
Rare variants and next-generation sequencing (NGS)  
Rare variants have become a focus in the recent past. Although GWAS have been 
successful in interrogating genetic variants for association with disease, GWAS are 
performed under the “common disease – common variant” hypothesis positing that 
common traits are caused by the combination of common variants with a small to 
moderate effect [58]. GWAS rely on genotyping preselected SNPs and imputing 
8 
 
ungenotyped variants based on local linkage disequilibrium (LD) of a set of some 
haplotypes from reference population. Imputation approaches have continually improved 
and are quite accurate for common variants [59, 60] but not as reliable for rare variants 
[61]. Therefore, imputed rare variants are typically removed from GWAS analysis.  
 
Recent advances in sequencing technologies have allowed to move toward 
comprehensive genome-wide approaches, enabling to accurately genotype rare variants 
generally defined as a variant with minor allele frequency (MAF) < 1-5%. These NGS 
technologies have the potential to improve our understanding the role of both common 
and rare variants in the underlying biological mechanisms of developing a disease. 
Whole-exome sequencing (WES) and whole-genome sequencing (WGS) are ideal 
approaches to identify novel variants and genes associated with complex traits. Most 
coding variants, however, are very rare, and thus an extremely large sample size is 
required to identify a single variant associated with a disease. There are significant 
computational and statistical challenges for these sequencing studies. Traditional single 
variant-based association tests, typically used for analysis of common variants, are 
underpowered to detect rare variants unless sample size and/or effect size is very large 
[62]. The disease-variant associations may be less accurate if computed by standard 
regression method for evaluating the effect. Instead of testing single variant individually, 
more powerful and computationally efficient approaches by aggregating the effects of 
rare variants have become a standard approach for association testing. 
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Many such approaches for testing association between rare variants within a pre-specified 
region and a disease have been proposed. Sequence-kernel association test (SKAT) is one 
of the most powerful rare variants analysis methods [63, 64]. The SKAT aggregates score 
test statistics. It is powerful when both risk and protective variants are mixed and when a 
small proportion of variants are causal [63]. Instead of summing up the square of 
weighted score test statistics, burden test treats the square of the sum of weighed score 
test statistics. The burden test is more powerful than SKAT when most of the variants are 
causal and have the same direction of effect [63].  
 
A recently-proposed scan-statistic-based test is another approach to detect the location of 
rare variant clusters influencing disease. Scan-statistic-based test was introduced into 
human genetics by Hoh et al [65] to locate susceptibility genes. Ionita-Laza et al. adapted 
this test to identify clusters of rare risk variants based on a likelihood ratio under a 
Bernoulli model proposed by Kulldorff [66] for disease association [67]. Variants within 
a functional protein-coding domain may be located in close proximity and may play a 
similar role in genetic mechanisms of a disease. Unlike association tests or other cluster 
detection analyses, the scan-statistic-based test can both detect the location of clusters 
and examine the association under the null hypothesis that probability of being a risk 
variant within a certain scan window equals to that outside the window. This approach is 
powerful when the disease risk variants significantly make a cluster in the window.  
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Dissertation Outline 
This dissertation work presents studies on gene-based association of genes with 
hippocampal sclerosis of aging, translation of AD-associated polymorphisms into 
functional candidates, and genetic regions containing rare variants associated with AD 
identified by scan statistic-based approach.In Chapter two, gene-based association tests of 
GRN, TMEM106B, ABCC9, and KCNMB2 and haplotype-based test of ABCC9 were 
performed. The major findings from this study were that the significant gene-based 
association between the ABCC9 gene and HS-Aging appeared to be driven by a region 
with a significant haplotype-based association. In addition, the haplotype of ABCC9 was 
associated with decreased ABCC9 expression. In Chapter three, the role of the non-
coding SNPs identified in the IGAP consortium GWAS were elucidated within a systems 
genetics framework. Systems genetics is a global approach to understand how genetic 
information flows from DNA to transcripts, proteins, metabolites, and ultimately 
diseases. Focusing on a causal relationship model in which SNP affects phenotype 
through mRNA, each IGAP SNP was evaluated whether it is a proxy of a coding variant 
or whether it is a regulatory variant. In Chapter four, genetic regions which contained risk 
or protective rare variants associated with AD were identified using a scan-statistic-based 
approach. The scan statistics with different settings were evaluated in TREM2 and 
TOMM40 as highly-replicated positive controls. Very similar scan statistic values were 
obtained when we specified the whole genome and chromosome as a large genetic 
region. The optimized window approach captured almost the entire gene in TREM2 and 
the single variant in TOMM40 as a meaningful cluster. Applying the optimized window 
approach across the genome, clusters harboring risk or protective variants for AD were 
11 
 
detected including within MUC6, NXNL1, and BCAM. The conclusion of the dissertation 
and future research interests are discussed in Chapter Five.  
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Table1.1. APOE isoforms encoded by two single nucleotide polymorphisms 
 rs429358  rs7412 
 Codon Amino acid  Codon Amino acid 
apoE2 TGC Cysteine  TGC Cysteine 
apoE3 TGC Cysteine  CGC Arginine 
apoE4 CGC Arginine  CGC Arginine 
A bold letter represents a nucleotide of each polymorphism 
 
 
 
1
3
 
Table1.2. Single nucleotide polymorphisms for Alzheimer’s Disease identified in the previous studies 
Gene Chr SNP Position Annotation 
1000 Genomes 
References 
MAF r2 D’ 
CR1 1 rs6656401 207,692,049 Intron 0.17   [41, 43] 
  rs3818361 207,784,968 Intron 0.18 0.83 0.94 [42, 45] 
  rs6701713 207,786,289 Intron 0.18 0.83 0.94 [44, 45, 68] 
  rs1408077 207,804,141 Intron 0.18 0.83 0.93 [45, 69] 
BIN1 2 rs6733839 127,892,810 
Regulatory region 
variant 
0.38   [41] 
  rs744373 12,789,4615 Intergenic variant 0.27 0.49 0.90 [42, 45, 70] 
  rs7561528 127,889,637 Intergenic variant 0.31 0.35 0.69 [44, 45, 69] 
INPP5D 2 rs35349669 234,068,476 Intron 0.46   [41] 
MEF2C 5 rs190982 88,223,420 Intron 0.37   [41] 
HLA-DRB5-
DBR1 
6 rs9271192 32,578,530 Intergenic variant 0.26   [41] 
CD2AP 6 rs10948363 47,487,762 Intron 0.25   [41] 
  rs9296559 47,452,270 Intron 0.25 1 1 [42] 
  rs9349407 47,453,378 Intron 0.25 1 1 [42, 44, 68] 
NME8 7 rs2718058 37,841,534 Intron 0.37   [41] 
ZCWPW1 7 rs1476679 100,004,446 Intron 0.30   [41] 
EPHA1 7 rs11771145 143,110,762 Intron 0.36   [41] 
  rs11767557 143,109,139 Intron 0.22 0.25 0.71 [42, 44] 
PTK2B 8 rs28834970 27,195,121 Intron 0.34   [41] 
A bold SNP ID represents the SNP identified the International Genomics of Alzheimer’s Project reported by Lambert et al [41]. 
Chr = chromosome; SNP = single nucleotide polymorphism; 1000 Genomes = 1000 Genomes Project Phase 3 in individuals of 
European ancestry; MAF = minor allele frequency  
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Table1.2. (Continued) 
Gene Chr SNP Position Annotation 
1000 Genomes 
References 
MAF r2 D’ 
CLU 8 rs9331896 27,467,686 Intron 0.40   [41] 
  rs11136000 27,464,519 Intron 0.39 0.91 0.97 [43, 45] 
  rs9331888 27,468,862 5 prime UTR 0.30 0.28 1 [43, 71] 
  rs2279590 27,456,253 
Non coding 
transcript exon 
0.41 0.83 0.93 [43] 
  rs7982 27,462,481 Missense 0.39 0.90 0.97  
  rs7012010 27,448,729 
Downstream gene 
variant 
0.28 0.18 0.83  
  rs1532278 27,466,315 
Non coding 
transcript exon 
variant 
0.39 0.91 0.97 [44] 
CELF1 11 rs10838725 47,557,871 Intron 0.28   [41] 
  rs1057233 47,376,448 3 prime UTR variant 0.32 0.17 0.97 [72] 
MS4A 11 rs983392 59,923,508 
Downstream 
intergenic 
0.41   [41] 
  rs670139 59,971,795 Intron 0.40 0.44 0.97 [42, 44] 
  rs4938933 60,034,429 Intergenic 0.40 0.70 0.85 [44] 
  rs610932 59,939,307 3 prime UTR variant 0.44 0.72 0.89 [42, 45] 
  rs662196 59,942,757 Intron 0.44 0.69 0.88 [45] 
  rs583791 59,947,252 Missense 0.48 0.68 0.87 [45] 
A bold SNP ID represents the SNP identified the International Genomics of Alzheimer’s Project reported by Lambert et al [41]. 
Chr = chromosome; SNP = single nucleotide polymorphism; 1000 Genomes = 1000 Genomes Project Phase 3 in individuals of 
European ancestry; MAF = minor allele frequency 
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Table1.2. (Continued) 
Gene Chr SNP Position Annotation 
1000 Genomes 
References 
MAF r2 D’ 
PICALM 11 rs10792832 85,867,875 
Downstream 
intergenic 
0.37   [41] 
  rs3851179 85,868,640 
Downstream gene 
variant 
0.37 0.99 0.99 [45, 73] 
  rs541458 85,788,351 Intergenic 0.32 0.64 0.90 [43] 
  rs561655 85,800,279 
Upstream gene 
variant 
0.35 0.77 0.92 [44] 
SORL1 11 rs11218343 121,435,587 Intron 0.043   [41] 
FERMT2 14 rs17125944 53,400,629 Intron 0.081   [41] 
SLC24A4-
RIN3 
14 rs10498633 92,926,952 Intron 0.22   [41] 
DSG2 18 rs8093731 29,088,958 Intron 0.012   [41] 
ABCA7 19 rs4147929 1,063,443 Intron 0.19   [41] 
  rs3764650 1,046,520 Intron 0.11 0.77 0.92 [42, 68] 
  rs72973581 1,043,103 Missense 0.053 0.012 1 [74] 
CD33 19 rs3865444 51,727,962 
Upstream gene 
variant 
0.31   [41, 42, 44] 
  rs3826656 51,726,613 
Upstream gene 
variant 
0.22 0.13 1  
  rs12459419 51,728,477 Missense 0.31 1 1  
CASS4 20 rs7274581 55,018,260 Intron 0.080   [41] 
A bld SNP ID represents the SNP identified the International Genomics of Alzheimer’s Project reported by Lambert et al [41]. 
Chr = chromosome; SNP = single nucleotide polymorphism; 1000 Genomes = 1000 Genomes Project Phase 3 in individuals of 
European ancestry; MAF = minor allele frequency 
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CHAPTER TWO 
Gene-based association study of genes linked to hippocampal sclerosis of aging 
neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2 
 
Abstract  
Hippocampal sclerosis of aging (HS-Aging) is a common neurodegenerative condition 
associated with dementia. To learn more about genetic risk of HS-Aging pathology, we 
tested gene-based associations of the GRN, TMEM106B, ABCC9, and KCNMB2 genes, 
which were reported to be associated with HS-Aging pathology in previous studies. 
Genetic data were obtained from the Alzheimer’s Disease Genetics Consortium (ADGC), 
linked to autopsy-derived neuropathological outcomes from the National Alzheimer’s 
Coordinating Center (NACC). Of the 3,251 subjects included in the study, 271 (8.3%) 
were identified as an HS-Aging case. The significant gene-based association between the 
ABCC9 gene and HS-Aging appeared to be driven by a region in which a significant 
haplotype-based association was found. We tested this haplotype as an expression 
Quantitative Trait Locus (eQTL) using two different public-access brain gene expression 
databases. The HS-Aging pathology protective ABCC9 haplotype was associated with 
decreased ABCC9 expression, indicating a possible toxic gain of function.  
 
Introduction 
Hippocampal sclerosis of aging (HS-Aging) is a high-morbidity brain disease in people 
of advanced age [75]. The prevalence of HS-Aging pathology ranges from 5 to 30% in 
older people in large autopsy series [23, 47, 76, 77]. Clinical signs and symptoms of HS-
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Aging are similar to those of Alzheimer’s disease (AD) with amnestic memory deficits 
[20, 21]. Because of the overlapping symptomology, HS-Aging is often clinically 
misdiagnosed as AD [19-21]. AD is characterized by the accumulation of amyloid 
plaques and neurofibrillary tangles [22], while HS-Aging is pathologically characterized 
by neuronal cell loss and gliosis in the hippocampus seen by hematoxylin and eosin 
(H&E) stain, which can occur unilaterally (~50%) or bilaterally [20, 23]. Whatever the 
laterality on H&E stain, the large majority of cases with HS-Aging show bilateral TAR 
DNA-binding protein 43 (TDP-43) pathology in limbic structures [24, 25]. Awareness of 
this common cause of dementia is rapidly increasing, and we recently recommended a 
revision of the terminology for describing this disease to cerebral age-related TDP-43 
with sclerosis (CARTS) [78]. However, here we will maintain use of the term HS-Aging 
because the neuropathologic databases we assessed did not include TDP-43 pathologic 
information until quite recently. 
 
Genetic risk factors for HS-Aging have been recently identified. Unlike AD, the 
apolipoprotein E (APOE) ε4 allele is not a risk factor for HS-Aging [19, 21, 25, 46, 47]. 
By contrast, the following four genes (in the chronological order they were so identified) 
have been reported to harbor risk alleles associated with HS-Aging pathology: Granulin 
(GRN) on chromosome 17q, Transmembrane protein 106B (TMEM106B) on 
chromosome 7p, ATP-binding cassette sub-family member 9 (ABCC9) on chromosome 
12p, and potassium channel subfamily M regulatory beta subunit 2 (KCNMB2) on 
chromosome 3q [21, 48-53].  
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Alleles near the coding portions of the GRN and TMEM106B genes were shown to have 
an association with HS-Aging using an allele test, following the known relationship of 
those two genes to frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-
TDP). Specifically, HS-Aging pathology was associated with the T-allele of the GRN 
single nucleotide polymorphism (SNP) rs5848 [49, 53, 79, 80]. For the other FTLD-
related gene, TMEM106B, persons with eventual autopsy-proven HS-Aging pathology 
were more likely to have the T-allele than controls [50, 53, 81]. We confirmed an 
increase in HS-Aging odds for each copy of the T-allele of TMEM106B rs1990622 [51].  
 
The connections of the ABCC9 and KCNMB2 genes to HS-Aging risk were discovered 
via genome-wide association studies (GWAS), which are neither helped nor biased by 
prior mechanistic hypotheses. The association of ABCC9 SNP rs704178 with HS-Aging 
pathology was demonstrated in a GWAS using a recessive mode of inheritance (MOI) 
[51]. The relationship of this locus with HS-Aging was subsequently tested in a different 
group of research subjects, and the association was replicated [52]. Beecham and 
colleagues reported the KCNMB2 SNP rs9637454 as the top SNP for HS pathology, 
although this association was not genome wide significant [48], and has not been 
replicated to date. 
 
In the present study, we examined the associations of these four putative risk SNPs with 
HS-aging pathology, using genetic data obtained from Alzheimer’s Disease Genetics 
Consortium (ADGC) linked to neuropathological outcomes from the National 
Alzheimer’s Coordinating Center (NACC) [51, 52]. Here we aggregated those data sets 
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to attain greater statistical power for gene-wide association analyses, for the purpose of 
understanding better the association of multiple (often co-inherited) gene variants with 
disease development. Thus, we tested GRN, TMEM106B, ABCC9, and KCNMB2 for 
gene-based associations with HS-Aging pathology by aggregating SNPs and indels (small 
insertions or deletions) on each of those genes. In addition, we focused on the interesting 
region located around intronic SNP rs704178 on the ABCC9 gene that was identified in 
the previous work, and analyzed haplotype associations of the region with HS-Aging 
pathology and ABCC9 gene expression.  
 
Material and methods 
Study subjects 
ADGC genotype data were linked to data from the National Institute on Aging (NIA)-
funded 36 AD Centers (ADCs) and NACC registry phenotype information. Of 3,730 
subjects with both genotype and autopsy information available to us, those who died at 
age 60 years or older were included in this study. Cases of HS-Aging were identified as 
patients who met at least one of the following criteria at autopsy; 1) the primary 
pathologic diagnosis was hippocampal sclerosis, 2) there was a contributing pathologic 
diagnosis of hippocampal sclerosis, or 3) medial temporal lobe sclerosis was present at 
autopsy. We then excluded 180 individuals who had FTLD with ubiquitin-positive 
inclusions, FTLD with no distinctive histopathology, FTLD-tau, or prion associated 
disease (Figure 2.1). 
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Quality control of the ADGC genotype data 
Standard quality control (QC) procedures were performed on the ADGC genotype data 
using PLINK v1.90a [82]. Markers were excluded based on the following criteria: (1) 
minor allele frequency (MAF) < 1%; (2) call rate per variant (SNPs and indels) < 95%, 
(3) Hardy-Weinberg equilibrium test in controls < 10−5. (Table 2.1). Samples were 
excluded based on the following criteria: (1) call rate per individual < 95%, (2) a high 
degree of relatedness per an estimated proportion of identical by descent (IBD) > 0.1875, 
(3) excess of ± 3.0 standard deviations of heterozygosity rate. Of the 3,407 individuals 
after the inclusion and exclusion criteria were applied, 3,330 passed the QC (Figure 2.1). 
 
Identifying ethnic outliers 
We performed principal component analysis (PCA) in EIGENSTRAT [83] using a 
linkage disequilibrium (LD) pruned subset of markers (pairwise r2 < 0.2) from our data 
merged to 1000 Genomes Project Phase 3 (1000 Genomes) [84] data after removing 
symmetric SNPs and flipping SNPs discordant for DNA strands between the two 
datasets. We then plotted the first and second principal components (PCs) for each 
individuals (n = 5,834: 2,504 from 1000 Genomes and 3,330 from the study) using the 
ggplot2 R package (version 2.2.0) [85] in R (version 3.2; http://www.r-project.org). 
Based on the PC plot, 79 study subjects were removed as ethnic outliers (Figure 2.1 and 
Figure 2.2). We reran the PCA for the remaining 3,251 European ancestries to derive 
orthogonal PCs which were used as covariates in the subsequent analyses. 
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Statistical analysis 
Gene-based association analysis 
Prior to gene-based association analyses, we performed the single variant association 
testing using logistic regression assuming each of the three most commonly used MOI 
(additive, dominant, and recessive) adjusted for age at death, sex and the top three PCs 
using PLINK v1.90a [82]. Gene-based association analyses were conducted using 
GATES (Gene-Based Association Test Using Extended Simes Procedure) [86] as 
implemented in the open-source software Knowledge-Based Mining System for Genome-
wide Genetic Studies (KGG; version 3.5) [86]. GATES is a gene-based association test 
that combines the p-values of variants within a gene obtained from single variant 
association testing described above. We assigned variants to genes based on their 
physical positions at the UCSC Genome Browser GRCh37/hg19 human assembly 
(https://genome.ucsc.edu/) [87], and defined gene boundaries as ± 5kb from 5’ and 3’ 
untranslated regions (UTRs). This gene-based association test adjusts for LD in European 
super population genotype data from the 1000 Genomes (1000 Genomes EUR) [84]. The 
input data files to KGG contained four columns: chromosome number, marker ID, 
marker position, and single variant association p-value. We then obtained overall p-
values for the associations of the target genes. Since those who live to advanced old age 
have a higher risk of HS-Aging pathology [25, 88], there is a possibility that those who 
died earlier would be always identified as a control even if they have a genetic risk. 
Therefore, for sensitivity analysis against these possible misclassifications, we further 
performed these gene-based association tests in cases and controls who died at age 80 
years or older. For the gene-based association test, statistical significance level was 
 
22 
 
defined using the Bonferroni correction, yielding α = 0.05/(4 genes ×3 MOI ×2 age 
groups) = 0.0021 for the four examined genes and three MOI.  
 
Haplotype-based association analysis for HS-Aging 
After identifying the HS-Aging risk-associated region on the ABCC9 gene by generating 
a regional association plot using LocusZoom software [89], we performed additional post 
hoc haplotype analysis for the variants on the region. First, we selected tag variants using 
a pairwise SNP tagging approach with r2 ≥ 0.8 based on the 1000 Genomes EUR in 
Haploview version 4.2 [90]. Maximum likelihood estimates of haplotype frequencies 
were computed using an expectation-maximization (EM) algorithm implemented in the 
functions haplo.em (for overall subjects) and haplo.group (for HS-Aging cases and 
controls) of the haplo.stats R package (version 1.7.7) [91] using R (version 3.2; 
http://www.r-project.org). The associations between common haplotypes (the estimated 
frequencies greater than 1% in entire subjects) and HS-Aging status assuming a recessive 
MOI were then tested with a haplotype score test adjusted for age at death, sex, and the 
top three PCs [92] implemented in the function haplo.score. The global and haplotype-
specific empirical p-values were obtained via 107 Monte-Carlo simulations. 
 
Haplotype-based expression Quantitative Trait Locus (eQTL) analysis for ABCC9 gene 
expression 
We examined the association of the haplotypes with ABCC9 gene expression, focusing 
on the haplotypes that were identified in association analysis for HS-Aging pathology. 
We retrieved ABCC9 gene expression values in human brain and genotype data from two 
 
23 
 
independent datasets: North American Brain Expression Consortium (NABEC) [93] and 
United Kingdom Brain Expression Consortium (UKBEC) [94].  
 
In the NABEC dataset, the expression data were available at Gene Expression Omnibus 
(GEO) public repository (http://www.ncbi.nlm.nih.gov/geo/) under the GEO accession 
GSE36192, consisting of two brain regions (cerebellum and frontal cortex) from 228 
neurologically normal donors. The genotype data were obtained from the database of 
Genotypes and Phenotypes (dbGaP: http://www.ncbi.nlm.nih.gov/gap) under the dbGaP 
study accession phs000249.v2.p1. After the QC procedure with the same settings as we 
did for the ADGC genotype data was applied, the genotype data were imputed using 
Michigan Imputation Server (https://imputationserver.sph.umich.edu/start.html) [95] with 
the following parameters: 1000 Genome Phase 3 v5 reference panel, Eagle v2.3 phasing 
[96], and EUR population. The imputed genotype with posterior probabilities < 0.9 were 
labeled as missing. Among the 228 NABEC subjects, 130 who died at age 30 years or 
older and passed the QC were included in the analysis (all of them were US Caucasians).  
 
In the UKBEC dataset, gene expression for ten brain regions (cerebellar cortex, frontal 
cortex, hippocampus, medulla, occipital cortex, putamen, substantia nigra, thalamus, 
temporal cortex, and white matter) and genotype data from 134 “neuropathologically 
normal” individuals were obtained at BRAINEAC website (http://www.braineac.org/). 
The dosage files downloaded from the website (accessed 6/28/2016) were converted into 
PLINK file format using Genome-wide Complex Trait Analysis (GCTA) software 
version 1.24.4 [97]. The haplotype-based association analyses on ABCC9 gene 
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expression were performed for the five haplotypes that were identified in the haplotype-
based association analysis for HS-Aging assuming an additive MOI.  
 
The analyses were carried out separately in the two datasets. We focused on ABCC9 gene 
expression through Illumina probe ID ILMN_1751453 in frontal cortex of the NABEC 
and through Affymetrix transcript ID t3446919 in the average of all ten regions of the 
UKBEC dataset. Expression data were quantile normalized and log2-transformed.  
 
Results 
Of the 3,251 included subjects from ADGC/NACC, 271 (8.3%) met at least one of the 
HS-Aging case criteria. Figure 2.3 shows the proportion of participants with HS-Aging 
pathology increased with age at death, from 3.1% (95% confidence interval (CI) is 1.6 to 
5.4%) in those aged less than 70 years to 15.7% (95% CI is 12.8 to 19.0%) in those aged 
90 years or older. The mean age at death in the cases was significantly higher than that in 
the controls (84.8 ± 8.4 years in the cases and 80.5 ± 8.8 years in the controls). No 
statistically significant differences were noted by case status and sex, APOE ε4 and 
microtubule-associated protein tau (MAPT) haplotype (H1 haplotype tagging rs8070723 
A-allele and H2 tagging G-allele) frequencies (Table 2.2). 
 
Single variant-based association 
Table 2.3 shows the most associated variants on each of the four genes defined gene 
boundaries as ± 5kb from 5’ and 3’ UTRs. The highest association signals came from 
SNPs on the ABCC9 gene (rs7966849; p = 7.1 × 10-6 with an assumed recessive MOI and 
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p = 4.4 × 10-5 with an assumed additive MOI) and on the KCNMB2 gene (rs73183328; p 
= 8.2 × 10-5 with an assumed additive MOI and p = 1.6 × 10-4 with an assumed dominant 
MOI). There was a series of small signals in high LD with the top SNP on the 
TMEM106B gene, and there was an associated region with small effects in low-to-
moderate LD with the top SNP on the ABCC9 gene.  
 
Gene-based association 
In the gene-based association analyses, 20, 222, 259 and 939 variants were mapped to the 
GRN, TMEM106B, ABCC9 and KCNMB2 genes, respectively. Table 2.4 shows the 
results of the gene-based association test in people aged 60 years. The ABCC9 gene had a 
significant gene-based association with HS-Aging assuming a recessive MOI when 
applying the Bonferroni correction (p = 2.4 × 10-4). There were nominally significant 
gene-based associations for the GRN gene assuming a recessive MOI, the TMEM106B 
gene assuming a recessive and an additive MOI, the ABCC9 gene assuming an additive 
MOI, and the KCNMB2 gene assuming an additive and a dominant MOI. For sensitivity 
analysis in people aged 80 years or older (n = 1,883: 203 in HS-Aging cases and 1,680 in 
controls), we confirmed the same results that the ABCC9 gene had a significant gene-
based association with HS-Aging assuming a recessive MOI (p = 0.0017) (Table 2.5).  
 
Haplotype-based association with HS-Aging 
The single-variant-based association plots (Figure 2.4) imply that the significant gene-
based association of the ABCC9 gene is driven by the region in which the most 
significant variants were located on the position 21,982,262 - 22,015,114 (all 
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chromosomal positions we describe are referent to human assembly GRCh37/hg19). The 
top SNP (rs7966849) in this study is in high LD with rs704180 (r2 = 0.926) which was 
identified as the predominant risk SNP of HS-Aging [51, 52]. Assuming a recessive MOI, 
there were 33 variants (30 SNPs and 3 indels) associated with HS-Aging pathology (each 
with p < 1.0 × 10-3) in this region, all of which are intronic. We selected four tag SNPs 
between exon 18 and 29 (Figure 2.4) of the ABCC9 gene when assuming a recessive 
MOI. The most frequent haplotypes were “Hap1” T-A-G-T (from 5’ to 3’) estimated to 
be present in 40.1% of observed chromosomes (32.1% in cases and 40.8% in controls), 
and “Hap2” C-C-A-C (36.8%; 43.7% in cases and 36.2% in controls). Hap1 was 
significantly associated with a lower risk of HS-Aging (score statistic = -2.747 and p = 
0.0061) and Hap2 with a higher risk of HS-Aging (score statistic = 4.277 and p = 3.3 × 
10-5). 
 
Haplotype-based expression Quantitative Trait Locus (eQTL) association with ABCC9 
gene expression 
In haplotype-based association tests assuming an additive MOI, Hap1 was significantly 
associated with ABCC9 gene expression in both datasets (p = 0.0026 in the NABEC and 
p = 0.024 in the UKBEC). Compared with the association with rs704180 only, Hap1 had 
a stronger association with ABCC9 gene expression in the NABEC (Table 2.6). 
  
Discussion 
In the large autopsy dataset derived from multiple research centers, we evaluated the 
genetic associations of four candidate genes (GRN, TMEM106B, ABCC9, and KCNMB2) 
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for HS-Aging pathology. We found significant gene- and haplotype-based associations of 
the ABCC9 gene with HS-Aging, and these approaches provide new insights into the 
other candidate genes and variants that are associated with HS-Aging. The haplotype 
made up of the risk alleles at the region (Hap2: C-C-A-C) was significantly 
overrepresented in HS-Aging cases, and thus could be a risk haplotype, while the 
opposite haplotype (Hap1: T-A-G-T) was significantly overrepresented in controls, and 
thus could be a protective risk factor. We further revealed that the protective haplotype 
(i.e., Hap1) was associated with down-regulation of ABCC9 gene expression, and the 
results were consistent in two independent datasets.  
 
Unlike the TMEM106B and GRN genes, the association between the ABCC9 gene and 
FTLD-TDP has never been reported. That is, the ABCC9 gene could potentially be a key 
gene on the distinction between FTLD-TDP and HS-Aging pathogenesis. The ABCC9 
gene encodes a transmembrane protein, a part of an ATP-sensitive potassium (KATP) 
channel complex. KATP channel consists of two distinct subunits: an inwardly rectifying 
K+ channel (Kir6.x) and a regulatory sulfonylurea receptor (SURx) [98]. When the ATP 
levels drop due to hypoxia/ischemia or other stressor, vascular smooth muscle cell KATP 
channels open to increase K+ efflux, voltage-activated calcium channels close to block 
Ca2+ entry, and in turn, vasodilatation is induced [99, 100]. Given the critical roles in 
regulation of vascular tone, KATP channel dysfunction may be involved in cardio- and 
cerebrovascular diseases. In mouse experiments, knock-out Kir6.1 (encoded immediately 
downstream from ABCC9 on chromosome 12) and Abcc9 led to hypertension, coronary 
artery vasospasm, and sudden cardiac death [101, 102]. In addition, Leverenz and 
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colleagues found in their community-based study that HS-Aging cases were more likely 
to have history of stroke, small vessel disease, and hypertension than AD cases [47]. Our 
group also reported that brains with HS-Aging pathology tended to have 
arteriolosclerosis in multiple cortical and subcortical regions [103]. We note that known 
mutations in the human ABCC9 gene lead to a toxic gain of function (“Cantu syndrome”) 
also are associated with human cerebrovascular pathology - a phenotype of “tortuous 
cerebral vessels” detected on neuroimaging [104]. These prior studies imply that 
cerebrovascular factors might be involved in developing HS-Aging via the KATP channel-
dependent activity [105]. In addition, we recently reported that human brain gene 
expressions that are triiodothyronine (T3) responsive were correlated with the ABCC9 
gene expression, and total T3 levels in cerebrospinal fluid (CSF) were significantly 
higher in HS-Aging cases than in controls [106]. Prior studies showed links between 
thyroid hormone (TH) levels and dementia [107-109], as well as TH levels and vascular 
diseases [110-112]. Therefore it is possible that the ABCC9 gene variants may help 
mediate links between TH dysregulation, cerebrovascular disease, and HS-Aging 
pathology.  
 
The TMEM106B gene did not have a significant gene-based association with HS-Aging 
when applying the Bonferroni correction, but nominal significance was found assuming a 
recessive and an additive MOI. Van Deerlin and colleagues identified rs1990622 T-allele 
as a risk factor for FTLD with TDP inclusions (FTLD-TDP) [113]. Here we report that 
rs3823612, which is in strong LD with rs1990622 (r2 = 0.975), is the variant on the 
TMEM106B gene that is most strongly associated with risk for HS-Aging pathology 
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assuming a recessive and an additive MOI. However, there are 108 gene variants (96 
SNPs and 12 indels) in near perfect LD with the top SNP rs3823612 over the gene (the 
range of r2 was from 0.930 to 0.996). Of the 108 variants, rs3173615 is a missense variant 
on exon 6, rs6460901 is a splice region variant, rs2302634 and rs2302633 are non-coding 
transcript exon variants, 19 variants are 5’ or 3’ UTR variants, 10 variants are upstream 
or downstream gene variants, and the remaining variants are intronic. Yu and colleagues 
reported that rs1990622 A-allele was associated with more advanced TDP-43 pathology 
which is the dominant feature of HS-Aging [114]. TDP-43 is also a major disease protein 
of other neurodegenerative diseases including FTLD and amyotrophic lateral sclerosis 
(ALS) [115]. Nicholson and colleagues showed that rs3173615 (missense variant on exon 
6), dictating the amino acid at codon 185 of threonine (ACC: T185) or serine (AGC: 
S185), was associated with higher TMEM106B protein levels in GRN mutation carriers 
[116]. Aberrant TDP-43 immunoreactivity is seen in both HS-Aging and FTLD-TDP, 
and rs1990622 A-allele is reported to be a risk allele of both HS-Aging and FTLD-TDP. 
However, these two diseases differ in clinical symptoms and pathological characteristics 
[25, 117]. 
 
The SNP on the KCNMB2 gene that was identified as a possible risk factor is rs9637454 
[48], while in the current study we found that rs73183328 was the most strongly 
associated variant assuming an additive and a dominant MOI. Nominally significant 
gene-based association of the KCNMB2 gene with HS-Aging were found assuming an 
additive and a dominant MOI, although the gene-based associations were not significant 
when applying the Bonferroni correction. The KCNMB2 protein is the transmembrane β2 
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subunit of the large-conductance Ca2+- and voltage-activated K+ (BK) channel. The 
channel is formed by pore-forming α-subunit encoded on the KCNMA1 gene 
(chromosome 10) and four β-subunits (β1 to β4) [118]. The β2 subunit induces the BK 
channel inactivation with the coexpressed α-subunit leading to neuronal excitability by 
inhibiting K+ currents [119]. Since inactivating BK channels are found in CA1 
hippocampal neurons [120], HS-Aging may be related to the KCNMB2 gene via a process 
involving BK channel activation. It seems remarkable that both GWAS-identified 
putative HS-Aging risk genes (ABCC9 and KCNMB2) encode proteins that modify 
potassium channels. 
 
There are limitations in this study. Since NACC data are derived from ADCs, the study 
design is not population-based. Also, HS pathologic diagnoses vary across calendar time 
and ADCs. Thus, there was probably some misclassification of HS-Aging diagnosis. 
However, neuropathologic evaluation is the gold standard for HS diagnosis, and thus the 
problem of misclassification, while ever-present, was minimized as much as possible. We 
did not obtain dense genetic information on the GRN gene. The previously identified SNP 
rs5848 as a HS-Aging risk SNP was removed in the process of the QC due to high 
missing rate. Therefore, we could not evaluate the GRN gene well in this study.  
 
In summary, we confirmed that the ABCC9 gene had the significant gene-based 
association with HS-Aging when assuming a recessive MOI. The significant gene-based 
association of the ABCC9 gene is driven by the region in which a significant haplotype-
based association was found. Although we did not find statistically significant gene-based 
 
31 
 
associations of the other three genes (i.e., GRN, TMEM106B, and KCMNB2) with HS-
Aging in this study, it does not mean that these genes are not associated with HS-Aging. 
Single variants may independently affect HS-Aging pathology rather than the entire gene, 
or there may be interactions between these genes conferring HS-Aging risk via other 
mechanisms, such as TDP-43 proteinopathies or ion channel dysfunction. In the future, 
we plan to examine what role the intronic region of the ABCC9 gene plays in developing 
HS-Aging pathology, and whether there are single variant-based and gene-based gene-
gene interactions among these four genes to HS-Aging. 
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Table 2.1. Quality control filters for single nucleotide polymorphism 
Criteria # of excluded variants # of passed variants 
MAF < 1% 29,429,731 8,613,031 
Call rate per variant < 95% 1,928,184 6,684,847 
HWE test in controls < 10-5 19,386 6,665,461 
MAF = minor allele frequency; HWE = Hardy-Weinberg equilibrium 
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Table 2.2. Comparison of selected characteristics between hippocampal sclerosis of aging 
cases and controls who died at age 60 years or older (n = 3,251) 
Variable 
Cases 
n = 271 
Controls 
n = 2,980 
p-value 
Age at death, mean (SD) 84.8 (8.4) 80.5 (8.8) <0.001 
Sex, n (%)    
 Male 124 (45.8) 1,458 (48.9) 0.349 
 Female 147 (54.2) 1,522 (51.1)  
APOE, n (%)a    
 -/- 114 (46.0) 1,207 (44.1) 0.749 
 -/ε4 109 (43.9) 1,216 (44.4)  
 ε4/ε4 25 (10.1) 314 (11.5)  
MAPT (rs8070723), n (%)b    
 H1/H1 176 (66.2) 1,773 (60.1) 0.146 
 H1/H2 77 (28.9) 1,022 (34.7)  
 H2/H2 13 (4.9) 154 (5.2)  
a APOE genotype information was available for n = 2,985. 
b MAPT genotype information was available for n = 3,215. 
SD = standard deviation; APOE = apolipoprotein E; MAPT = microtubule-associated 
protein tau. 
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Table 2.3. Most associated variant with hippocampal sclerosis of aging in four genes using a logistic regression model assuming a 
recessive/additive/dominant mode of inheritance in people who died at age 60 years or older (n = 3,251) 
Gene MOI Variant 
Risk/protective 
alleles 
RAF 
in cases 
RAF 
in controls 
OR (95% CI)a p-value 
GRN        
 REC rs72824731 C/G 9.5 8.4 3.88 (1.64 – 9.22) 0.0021 
 ADD 
rs2879096 T/C 28.6 24.4 
1.25 (1.02 – 1.53) 0.032 
 DOM 1.38 (1.07 – 1.78) 0.014 
TMEM106B        
 REC 
rs3823612 G/C 64.6 56.5 
1.53 (1.19 – 1.98) 0.0011 
 ADD 1.40 (1.16 – 1.68) 3.6 × 10-4 
 DOM rs13229988 A/G 64.0 56.4 1.67 (1.16 – 2.40) 0.0062 
ABCC9        
 REC 
rs7966849 A/G 60.3 51.2 
1.84 (1.41 – 2.40) 7.1 × 10-6 
 ADD 1.46 (1.22 – 1.76) 4.4 × 10-5  
 DOM rs829080 C/T 59.1 40.9 1.76 (1.18 – 2.62) 0.0057 
KCNMB2        
 REC rs13091964 T/C 96.1 92.9 1.84 (1.15 – 2.96) 0.011 
 ADD 
rs73183328 A/G 5.0 2.2 
2.42 (1.56 – 3.76) 8.2 × 10-5 
 DOM 2.40 (1.52 – 3.78) 1.6 × 10-4 
a Adjusted for age at death, sex and the top three principal components 
MOI = mode of inheritance; RAF = risk allele frequency; OR = odds ratio; CI = confidence interval; REC = recessive; ADD = 
additive; DOM = dominant 
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Table 2.4. Gene-based associations of the target four genes with hippocampal sclerosis of aging assuming a 
recessive/additive/dominant mode of inheritance in people who died at age 60 years or older (n = 3,251) 
Gene 
# of 
variants 
Start position End position 
Gene-based p-value 
REC ADD DOM 
GRN 20 42,417,491 42,435,470 0.012 0.16 0.090 
TMEM106B 222 12,245,848 12,281,890 0.028 0.0089 0.068 
ABCC9 259 21,945,324 22,094,628 2.4 × 10-4 0.0014 0.26 
KCNMB2 939 178,249,224 178,567,217 0.57 0.0079 0.016 
REC = recessive; ADD = additive; DOM = dominant 
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Table 2.5. Gene-based associations of the target four genes with hippocampal sclerosis of 
aging assuming a recessive/additive/dominant mode of inheritance in people who died at 
age 80 years or older (n = 1,883) 
Gene 
 Gene-based p-value  
REC ADD DOM 
GRN 0.24 0.035 0.026 
TMEM106B 0.027 0.0032 0.0070 
ABCC9 0.0017 0.0099 0.18 
KCNMB2 0.23 0.014 0.015 
REC = recessive; ADD = additive; DOM = dominant 
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Table 2.6. Haplotype association with ABCC9 gene expression in human brain assuming 
an additive mode of inheritance 
 NABEC 
(Frontal cortex; n = 130 brains) 
 UKBEC 
(10 brain regions; n = 134 brains) 
 Score statistic a p-value  Score statistic a p-value 
Hap1 -2.968 0.0026  -2.250 0.024 
Hap2 1.450 0.15  1.740 0.081 
Hap3 1.686 0.091  -0.048 0.96 
Hap4 0.214 0.83  -0.822 0.41 
Hap5 0.878 0.38  1.952 0.051 
Global 10.255 0.034  8.455 0.074 
      
rs704180 only  0.010   0.011 
a A positive sign indicates up-regulation of ABCC9 gene expression and vice versa. 
 
NABEC = North American Brain Expression Consortium (GEO accession: GSE36192); 
UKBEC = United Kingdom Brain Expression Consortium (http://www.braineac.org/). 
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Figure 2.1. Flow diagram of the subjects included in the analyses. Genetic data were 
obtained from subjects in ADGC who had the NACC individual IDs. Phenotype data 
were available from the neuropathological dataset in NACC. The inclusion/exclusion 
criteria, quality control and removal of ethnic outliers were applied in order. 
ADGC = Alzheimer’s Disease Genetics Consortium; NACC = National Alzheimer’s 
Coordinating Center; NP = neuropathological dataset; HS-Aging = hippocampal sclerosis 
of aging 
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Figure 2.2. The first and second principal components plots along with 1000 genome 
reference samples. Block dot indicates individuals in this study. We chose individuals 
within the red dotted circle based on Euclidean distance from an individual with 
maximum first and second principal components. 
AFR = African; AMR = Admixed American; EAS = East Asian; EUR = European; SAS 
= South Asian 
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Figure 2.3. Proportion and 95% confidence interval of hippocampal sclerosis of aging 
cases 
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Figure 2.4. Estimation of haplotype frequencies and association using four tag single 
nucleotide polymorphisms on the ABCC9 gene when assuming a recessive mode of 
inheritance. Box indicates an exon. 
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CHAPTER THREE 
Translating Alzheimer’s disease risk polymorphisms into functional candidates 
: a survey of IGAP genes 
 
Abstract  
Alzheimer’s disease (AD) is the most common form of dementia. The report with the 
largest numbers of cases and controls was the International Genomics of Alzheimer’s 
Project (IGAP), a consortium to discover the genetic landscape of AD that included 
74,046 individuals to show significant AD-associations with 19 SNPs. However, we have 
relatively little understanding of the functional impact of these loci in regards to AD 
pathogenesis. In this study, we elucidated the role of the non-coding SNPs identified in 
IGAP hypothesizing that each IGAP SNP is a proxy of a coding variant and/or a 
regulatory variant. Our genetic data were obtained from the Alzheimer's Disease 
Sequencing Project (ADSP). For the first hypothesis, rs2296160 in CR1, rs9270303, 
rs1049092, and rs1049086 in HLA-DRB5, rs2405442 and rs1859788 in ZCWPW1, rs7982 
in CLU, rs12453 and rs7232 in MS4A6A, and rs3752246 in ABCA7 may be proxies of 
coding SNPs. For the second hypothesis, rs6656401 in CR1, rs10838725 in CELF1, and 
rs8093731 in DSG2 may be regulatory SNPs affecting AD-associated gene expression. 
Our approach for identifying proxies and examining eQTL lessens the impact of the 
crude gene assignment, although this still remains an open question in the field. 
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Introduction 
Dementia is a clinical state caused by neurodegeneration and characterized by a loss of 
function in cognitive domains and behavior. Alzheimer’s disease (AD) is the most 
common form of dementia, accounting for over 50% of dementia cases [1]. Although it 
has been more than 100 years since Alois Alzheimer published “About a Peculiar Disease 
of the Cerebral Cortex” in 1907 [3], the exact cause of AD is yet to be identified. 
Amyloid β (Aβ) protein and hyperphosphorylated tau aggregates in the brain are 
considered to be the key pathological hallmarks in AD patients [4, 5]. A predominant 
mechanistic hypothesis for AD pathogenesis is the “amyloid cascade hypothesis” that 
suggests that AD is caused by lack of Aβ clearance, which triggers downstream neuronal 
injury such as synaptic and neuronal loss, enhanced neuroinflammation, tau 
hyperphosphorylation, and eventually the clinical symptoms of AD [6].  
 
Familial AD, which often occurs early in life, is linked mainly to mutations in three 
genes: amyloid precursor protein (APP) and the presenilin proteins (PSEN1 and PSEN2) 
[8], which generally cause a shift in Aβ production from Aβ40 to less soluble and more 
neurotoxic Aβ42 (e.g., Volga German mutation in PSEN2 and Iberian mutation in APP) 
[26-29], an increased total Aβ levels (Swedish mutation in APP) [30], and an increased 
protofibril formation of Aβ (Arctic mutation in APP) [31]. On the other hand, late-onset 
AD (LOAD), which accounts for 95% of all AD cases [32], has a more complex genetic 
architecture. The ε4 allele of apolipoprotein E (APOE) gene is the most well-established 
susceptibility gene for LOAD. There are three apoE isoforms, apoE2 (cys112, cys158), 
apoE3 (cys112, arg158), and apoE4 (arg112, arg158), determined by two single 
 
44 
 
nucleotide polymorphisms (SNPs) rs429358 (T/C) and rs7412 (C/T) located on 
chromosome 19q13. These isoforms have different effects on Aβ metabolism, influencing 
age of onset of Aβ deposition. It is suggested that the binding ability of the apoE isoforms 
to Aβ follows the increasing order of apoE2, apoE3 and apoE4, and thus apoE2 and 
apoE3 inhibit the aggregation and enhance the clearance of Aβ compared to apoE4 [33]. 
The APOE alleles are also reported to be associated with tau levels in CSF [34, 35]. This 
association, however, has not been established as thoroughly as the association between 
APOE alleles and Aβ deposition [36].  
 
A series of genome-wide association studies (GWAS) have identified AD-associated 
SNPs in addition to the APOE alleles. The report with the largest numbers of cases and 
controls was the International Genomics of Alzheimer’s Project (IGAP), a consortium to 
discover the genetic landscape of AD that included 74,046 individuals to show significant 
AD-associations with 19 SNPs by meta-analyzing GWAS from four component consortia 
[41]. The SNPs are in or close to genes that include CR1, BIN1, INPP5D, MEF2C, 
CD2AP, NME8, EPHA1, PTK2B, PICALM, SORL1, FERMT2, SLC24A4-RIN3, DSG2, 
CASS4, HLA-DRB5-DBR1, CLU, MS4A6A, ABCA7, CD33, ZCWPW1, and CELF1 
(Table 1.2). Although GWAS have succeeded in revealing numerous susceptibility 
variants for AD, it is difficult to determine whether the genes and SNPs at these loci are 
functional and to understand how they contribute to AD pathogenesis. 
 
Genetic variants located in coding regions are much less frequent than those in non-
coding regions (about only 1% of variants are within a protein-coding sequence) [54]. 
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However, it is estimated that about 85% of the mutations with large effects on diseases 
are located in protein-coding functional regions [55]. To understand disease development 
mechanisms that underlie AD-associated genetic variants, identifying functional genes 
and/or variants is an important challenge. Functional variants may be located in a coding 
region, an alternative splicing region, or a regulatory region such as promoter, operator, 
insulator, enhancer or silencer. Nonsynonymous variants may have effects on the protein 
structure and function. Many Mendelian diseases are due to nonsynonymous mutations 
causing deleterious amino acid substitutions. Synonymous mutations occur in the coding 
region but do not change the amino acid sequence. These variants were referred to as 
“silent mutations” until recently [56]. Several synonymous mutations have been reported 
to affect mRNA splicing and stability, gene expression, and protein folding and function 
[56]. Other disease-associated genetic variants are located in the intronic and intergenic 
regions (i.e., non-coding regions) which may contain regulatory or splice sites. Intronic 
and intergenic variants may have an important role in regulating expression level of 
disease-associated genes and modulating translation efficiency and stability [57].  
 
In this study, we elucidated the role of the non-coding SNPs identified in the IGAP 
consortium (hereinafter referred to as “IGAP SNPs”) within a systems genetics 
framework. Systems genetics is a global approach to understand how genetic information 
flows from DNA to transcripts, proteins, metabolites, and ultimately diseases [121]. 
Figure 3.1A shows three possible pathways linking a SNP, a transcript (mRNA), and a 
phenotype [121-123]. The first model is the causal relationship model in which the SNP 
affects phenotype by acting through mRNA. Second, the reactive model proposes that the 
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SNP requires the phenotype to affect the mRNA. The third model is the independent 
model in which the SNP affects mRNA and phenotype independently. Focusing on these 
models in this study, we hypothesized that each IGAP SNP is: (1) a proxy of a coding 
SNP (Figure 3.1B and 3.1C) or (2) a regulatory SNP (Figure 3.1D). One frequently used 
approach to test the first hypothesis is to identify coding SNPs in strong linkage 
disequilibrium (LD) with the SNP identified by GWAS. LD is generally measured using 
the squared correlation coefficient (r2) between two SNPs, and the most widely used 
threshold is r2 ≥ 0.8. For the second hypothesis, expression quantitative trait locus 
(eQTL) analysis can be used. eQTL is a genetic locus that contributes to variation in gene 
expression. By mapping eQTL, we investigate how the SNPs regulate gene expression.  
 
Material and methods 
Genetic datasets 
Our genetic data were obtained from the Alzheimer's Disease Sequencing Project 
(ADSP) with whole exome sequence (WES) data to limit the possibility of imputation 
errors. ADSP is comprised of 18 cohorts from the Alzheimer's Disease Genetic 
Consortium (ADGC) and 6 from the Cohorts for Heart and Aging Research in Genomic 
Epidemiology (CHARGE) Consortium (Table 3.1). There were 10,913 unrelated subjects 
with WES data in ADSP. For our study, we limited the subjects to those who had AD 
diagnosis information and who were 65 years or older at the last visit or at death, yielding 
a total of 10,468 ADSP subjects with WES data (Figure 3.2). 
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Gene expression datasets 
Quality-controlled microarray gene expression from blood samples and whole genome 
sequence (WGS) datasets were obtained from the Alzheimer's Disease Neuroimaging 
Initiative (ADNI) database (available through http:// adni.loni.usc.edu). We included 661 
subjects aged 65 years or older who had both gene expression and WGS data available. 
We considered AD diagnosis (normal, mild cognitive impairment (MCI), or AD) closest 
to the year when the blood sample was drawn. 
 
We retrieved human brain gene expression and genotype dataset from the North 
American Brain Expression Consortium (NABEC) [93] and United Kingdom Brain 
Expression Consortium (UKBEC) [94]. Details are described in our previous report 
[124]. Briefly, the NABEC gene expression data in two brain regions (cerebellum and 
frontal cortex) were available at Gene Expression Omnibus (GEO) public repository and 
the genotype data were obtained from the database of Genotypes and Phenotypes 
(dbGaP: http://www.ncbi.nlm.nih.gov/gap). After performing standard QC procedures, 
we imputed the genotype data using the Michigan Imputation Server 
(https://imputationserver.sph.umich.edu/start.html) [95, 96] with the following 
parameters: 1000 Genome Phase 3 v5 reference panel, Eagle v2.3 phasing [96], and EUR 
population. Of the 228 neurologically normal donors, 119 subjects who died at age 65 
years or older and passed QC were included in the analysis (all were US Caucasians). 
The UKBEC gene expression in ten brain regions (cerebellar cortex (CRBL), frontal 
cortex (FCTX), hippocampus (HIPP), medulla (MEDU), occipital cortex (OCTX), 
putamen (PUTM), substantia nigra (SNIG), thalamus (THAL), temporal cortex (TCTX), 
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and white matter (WHMT)) and the genotype data in 134 neuropathologically normal 
individuals were obtained from the BRAINEAC website (http://www.braineac.org/). The 
dosage genotype data were converted into PLINK file format using Genome-wide 
Complex Trait Analysis (GCTA) software version 1.24.4 [97].  
 
Since the NABEC and UKBEC datasets do not have AD diagnosis information, we 
obtained two datasets to examine whether the levels of gene expressions were different 
between AD statuses. The first dataset was derived from AD cases and controls available 
at Gene Expression Omnibus (GEO) public repository 
(http://www.ncbi.nlm.nih.gov/geo/) under the GEO accession GSE5281 [125]. The gene 
expression data consisted of 9 AD cases and 13 controls in entorhinal cortex (EC), 10 AD 
cases and 12 controls in hippocampus (HIPP), 16 AD cases and 12 controls in medial 
temporal gyrus (MTG), 8 AD cases and 13 controls in posterior cingulate (PC), 23 AD 
cases and 11 controls in superior frontal gyrus (SFG), and 19 AD cases and 12 controls in 
primary visual cortex (VCX). The range of age at death was 63 to 102. The second was 
Allen Institute data downloaded at http://aging.brain-map.org/ derived from 38 AD cases 
and 47 controls (AD diagnosis was based on NINCDS-ADRDA Alzheimer's Criteria) in 
white matter (FWM), hippocampus (HIPP), parietal cortex (PCx), and temporal cortex 
(TCx) brain regions. The range of age at death was 77 to 100+. 
 
We excluded probes in Affymetrix that targeted transcripts from different genes (i.e., 
probes with “_x” suffix) if a more reliable probe was available. We also excluded 
monoallelically expressed genes including genes on chromosomes X and Y, and HLA- 
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genes (i.e., HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, 
HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DQB2, HLA-DRA, 
HLA-DRB1, HLA-DRB5, HLA-E, HLA-F, HLA-G, HLA-J, HLA-P, and HLA-T). 
Expression data were normalized and log2-transformed.  
 
Statistical analysis 
Hypothesis 1: identified IGAP SNPs are proxies of coding SNPs 
For each of the 21 IGAP SNPs (including CD33 and DSG2, although the SNPs 
rs3865444 and rs8093731 were reported not to reach statistical significance on meta-
analysis in IGAP [41]), we first identified SNPs in the nearby coding-regions showing 
strong LD (r2 ≥ 0.8) and moderate LD (0.4 ≤ r2 < 0.8) by using 1000 Genomes Project 
Phase 3 in individuals of European ancestry (1000 Genomes EUR) [84]. We performed 
association tests under an additive mode of inheritance (MOI) assumption for the coding 
SNPs, using logistic regression adjusted for age at the last visit or death, sex, and the top 
5 principal components (computed in PLINK v1.90a [82]). The pathogenic nature of 
nonsynonymous SNPs associated with AD was predicted by SIFT (http://sift.jcvi.org/) 
[126] and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) [127] which are in silico 
algorithm tools to predict the effect of amino acid substitution on a protein function.  
 
Hypothesis 2: identified IGAP SNPs are regulatory SNPs 
We evaluated whether the IGAP SNPs were cis- or trans-eQTL on the same chromosome 
as genes. We defined a locus within 1Mb of the 5′ or 3′ ends of the gene as cis-eQTL, and 
a locus more than 1Mb away from the transcription site as a trans-eQTL (Figure 3.1E). 
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We first tested the association between each of the IGAP SNPs and each of all the gene 
expression profiles, assuming an additive MOI as implemented in PLINK v1.90a [82]. 
We then examined whether the levels of gene expression modified by the IGAP SNPs 
were different between AD statuses. An analysis of covariance (ANCOVA) with sex and 
age as covariates was applied to each comparison for all gene expressions identified in 
the eQTL analysis. 
 
For all analyses, we converted the nominal p-values into false discovery rate adjusted p-
values (FDR adjusted p-value) using the Benjamini-Hochberg procedure [128] and 
defined associations with FDR adjusted p-value < 0.05 as significant. 
 
Results 
We considered individuals with either prevalent or incident AD at baseline (year 0) as 
AD cases in ADSP. Descriptive characteristics of the individuals are shown in Table 3.2. 
5,374 (51.3%) were AD cases. 
 
Hypothesis 1: identified IGAP SNPs are proxies of coding SNPs 
We identified 10 exonic SNPs which were in strong LD (r2 ≥ 0.8) and 16 SNPs in 
moderate LD (0.4 ≤ r2 < 0.8) with the IGAP SNPs based on 1000 Genomes EUR (Table 
3.3). We confirmed that the several exonic SNPs demonstrated statistically significant 
associations with AD after FDR adjustment, including rs2296160 in CR1, rs9270303, 
rs1049092, and rs1049086 in HLA-DRB5, rs2405442 and rs1859788 in ZCWPW1, rs7982 
in CLU, rs12453 and rs7232 in MS4A6A, and rs3752246 in ABCA7 (Table 3.4). The 
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association between rs4844600 in CR1 and AD was not confirmed because of the lack of 
WES data in ADSP. Of these 10 coding SNPs, 5 SNPs (rs2296160 in CR1, rs9270303 in 
HLA-DRB1, rs1859788 in PILRA, rs3752246 in ABCA7, and rs7232 in MS4A6A) are 
nonsynonymous (Table 3.5). When we analyzed the nonsynonymous SNPs with SIFT 
and Polyphen-2, rs2296160, rs9270303, rs1859788, and rs3752246 were predicted to 
have minimal impact on their respective proteins (Table 3.5). In contrast, the minor allele 
of rs7232 was predicted to be deleterious and possibly damaging to MS4A6A protein. 
 
Hypothesis 2: identified IGAP SNPs are regulatory SNPs 
Table 3.6 shows gene expressions in the blood that were significantly associated with the 
IGAP SNPs, reaching FDR adjusted significance level. We found that the protective 
allele of rs1476679 in ZCWPW1 was strongly associated with decreased expression of 
multiple PILRB probe sets and TRIM4 expression, and associated with increased 
expressions of ZKSCAN1I, GATS, and PVRIG. The protective allele of rs11771145 in 
EPHA1 was associated with increased LOC154761 expression. The risk allele of 
rs28834970 in PTK2B exhibited cis-eQTL for multiple probe sets for its own expression 
and for the contiguous gene TRIM35. This allele also had trans-association with NSAP11. 
The risk allele of rs10838725 was associated with increased MYBPC3 expression. The 
protective allele of rs983392 was associated with decreased expressions of MS4A6A and 
another family members, MS4A4A. The protective alleles of rs8093731 in DSG2 and 
rs7274581 in CASS4 appeared to be trans-eQTLs. Of these significant gene expressions 
in the blood, only MYBPC3 (11725151_at) potentially regulated by the CELF1 SNP was 
significantly associated with AD status. 
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The FDR adjusted significant associations between the IGAP SNPs and brain gene 
expressions in NABEC and UKBEC are shown in Table 3.7. In NABEC, the protective 
allele of rs10792832 in PICALM was significantly associated with increased expression 
of MRGPRD in CRBL. The protective allele of rs8093731 in DSG2 exhibited trans-
eQTL for the expression of three genes, DLGAP1, NETO1, and KCNG2. The minor allele 
of rs7274581, which is also protective, was significantly associated with the PCK1 
expression in CRBL. Of these patterns, the DLGAP1 and NETO1 expressions in FCTX 
were highly correlated (r2 = 0.78) (Figure 3.3). In UKBEC, rs6656401 in CR1 acted as an 
eQTL for several genes, COL9A2, CERS2 (also known as KASS2), ARHGEF2, CNTN2, 
and CDK18 (also known as PCTK3 and PCTAIRE3) in MEDU, and CR1 itself in the 
average of all ten regions (AveALL) and WHMT. The genes potentially regulated by the 
CR1 SNPs were highly correlated with each other except CR1 expression (r2 = 0.68 to 
0.89) (Figure 3.4). 
 
In comparison with AD controls using GSE5281, AD cases had significantly lower 
expressions of DLGAP1 in MTG and SFG, NETO1 in EC, MTG, PC, and SFG, KCNG2 
in MTG, CR1 in MTG, and ARHGEF2 in EC. On the other hand, AD cases had 
significantly higher expressions of DLGAP1 in HIP, COL9A2, CERS2, and CR1 in EC, 
and ARHGEF2 in PC (Table 3.8 and Table 3.9). For the Allen Institute dataset, 
significantly higher expressions of KCNG2, CNTN2, ARHGEF2, and CDK18 in AD 
cases have seen only in TCx (Table 3.10). 
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Discussion 
Although recent studies have identified novel GWAS loci that affect AD risk, we have 
relatively little understanding of the functional impact of these loci in regards to AD 
pathogenesis. In this study, we examined the possible functional effects of the IGAP 
SNPs on AD under two hypotheses: “the IGAP SNP is a proxy of a coding SNP” and 
“the IGAP SNP is a regulatory SNP”. For the first hypothesis, rs2296160 in CR1, 
rs9270303, rs1049092, and rs1049086 in HLA-DRB5, rs2405442 and rs1859788 in 
ZCWPW1, rs7982 in CLU, rs12453 and rs7232 in MS4A6A, and rs3752246 in ABCA7 are 
proxies of coding SNPs. For the second hypothesis, rs6656401 in CR1, rs10838725 in 
CELF1, and rs8093731 in DSG2 are associated with gene expression, although whether 
these SNPs are proxies for the functional regulatory SNP or functional themselves 
requires further studies. 
 
Hypothesis 1: identified IGAP SNPs are proxies of coding SNPs 
CR1 SNPs 
The IGAP SNP rs6656401 in CR1 was the most striking SNP in this study for several 
reasons. First, there were 2 coding SNPs (one is synonymous and the other is 
nonsynonymous) in strong LD with the IGAP SNP. Second, the IGAP SNP acted as cis- 
or trans-eQTL for the several gene expressions in the brain. Last, these expressions were 
associated with AD. CR1, located on chromosome 1q32.2, encodes complement receptor 
1 in a cluster of complement-related proteins which plays an important role in the 
immune system [129]. The CR1 protein is a receptor for complement fragments binding 
to Aβ, and thus the change in CR1 protein structure and expression levels may be related 
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to Aβ clearance [130]. We found the two coding SNPs, rs4844600 and rs2296160, which 
were in strong LD with the IGAP SNP rs6656401. The coding SNP rs2296160 is 
nonsynonymous, causing alanine-to-threonine amino acid substitution at codon position 
2419 (A2419T), while the SNP rs4844600 is synonymous (E60E). The IGAP SNP as 
well as the coding SNPs acted as cis-eQTL for CR1 expression itself (Figure 3.5). The 
most associated SNP with the CR1 expression was the nonsynonymous SNP rs2296160. 
This may imply that the change in CR1 protein structure may change the expression level 
of the gene itself through an autoregulatory mechanism. 
 
Furthermore, the higher CR1 expression detected by the probe set 244313_at in EC 
increased the risk of AD in GSE5281 dataset. Consistent with our findings, the SNP 
rs1408077 in CR1, which is in strong LD with the IGAP SNP rs6656401, was reported to 
be associated with loss of EC thickness [69], and the IGAP SNP rs6656401 A carriers 
had smaller local gray matter volume in EC of young health adults which may lead to an 
increased risk of LOAD [131]. These results may indicate that there is a causal 
relationship between CR1 SNPs, CR1 expression, and AD development, although we 
cannot mention which model this relationship is on: causal model or reactive model in 
Figure 3.1.  
 
Other gene expressions than CR1 potentially regulated by CR1 SNPs were highly 
correlated with each other in MEDU in UKBEC. These genes are highly expressed in 
oligodendrocytes 
(http://web.stanford.edu/group/barres_lab/brainseqMariko/brainseq2.html) [132]. The 
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COL9A2 and CERS2 genes were over-expressed in EC of AD cases. The ARHGEF2 gene 
was over-expressed in PC and TCx of AD cases and under-expressed in EC of AD cases. 
The genes CNTN2 and CDK18 were significantly over-expressed in TCx of AD cases. In 
future work, gene co-expression network analysis will be required to understand how 
these gene expressions affect in each of the brain regions of AD cases. 
 
ZCWPW1 SNPs 
ZCWPW1 (zinc finger, CW type with PWWP domain 1) is located on chromosome 
7q22.1. We found two coding SNPs, rs2405442 and rs1859788, which were in strong LD 
with the IGAP SNP rs1476679. The coding SNP rs1859788 is nonsynonymous, causing 
glycine-to-arginine amino acid substitution at codon positions 78 (G213R). The IGAP 
SNP as well as the coding SNPs acted as cis-eQTLs for three gene expressions (GATS, 
TRIM4, and PILRB) in the blood, although we did not find significant associations 
between these blood gene expressions and AD.  
 
MS4A6A SNPs 
MS4A6A, located on chromosome 11q12.2, encodes a member of membrane-spanning 
4A gene family (membrane-spanning 4A domains, subfamily A, member 6A). We also 
found two coding SNPs, rs12453 and rs7232, which were in strong and moderate LD 
with the protective IGAP SNP rs983392. The coding SNP rs7232 is nonsynonymous, 
causing threonine-to-serine amino acid substitution at codon positions 213 (T213S), 
while the SNP rs12453 is synonymous (L137L). The IGAP SNP as well as the coding 
SNPs affected MS4A6A expression itself and its gene family MS4A4A in the blood. 
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However, we did not find FDR adjusted significant associations between these blood 
gene expressions and AD. MS4A genes are highly expressed in hematopoietic cells, and 
involved in the regulation of calcium signaling [133]. Although the function of MS4A6A 
protein are still unknown, it is possible that the MS4A6A SNPs is linked to AD via 
deregulation of calcium signaling implicated in neurodegenerative diseases [134, 135].  
 
CLU SNPs 
We confirmed synonymous SNP rs7982 was in strong LD with the IGAP SNP rs9331896 
and was protectively associated with AD. However, we found no significant gene 
expressions regulated by the CLU IGAP SNP and the synonymous SNP. CLU, also 
known as apolipoprotein J, is located in chromosome 8p21.1, and encodes clusterin. 
Clusterin directly influences Aβ, regulating the conversion of Aβ into insoluble forms 
[136, 137]. CLU has mainly two isoforms, nuclear CLU (nCLU, isoform 1) and secretary 
CLU (sCLU, isoform 2) with different functions. The sCLU form is pro-survival, while 
nCLU is pro-apoptotic [138]. Since the coding SNP rs7982 is synonymous, it would 
affect alternative splicing as Ling et al. showed that the protective SNP rs11136000 
(which is in almost perfect LD with rs7982 in 1000 genomes EUR) was associated with 
increased nCLU expression level [139]. We would need to examine how the isoforms 
affects Aβ clearance in future. 
 
HLA-DRB5-DRB1 SNPs 
The IGAP SNP rs9271192 is located in intergenic region (chromosome 6p21.32), 
contiguous to HLA class II genes (HLA-DR, -DQ and -DP). There were two coding 
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SNPs which were in strong or moderate LD with the IGAP SNP: the nonsynonymous 
rs9270303 is in HLA-DRB1 and the synonymous rs1049092 is in HLA-DQB1. Several 
HLA-DR and HLA-DQ genes are monoallelically expressed. There are three classes of 
monoallelically expressed genes [140, 141]. One is the autosomal imprinted genes 
regulated in a parent-of-origin specific manner. The second one is X-inactivated. The last 
class is for randomly monoallelically expressed genes in autosome, in which several 
immune system genes are included [140, 141]. Given epigenetic association between 
DNA methylation in HLA-DRB5 and AD pathology [142], allele specific expression may 
impact on biological function related to AD.  
 
ABCA7 SNPs 
We confirmed that nonsynonymous SNP rs3752246 was in strong LD with the IGAP 
SNP rs4147929 and was associated with AD risk. However, we found no significant gene 
expressions regulated by the ABCA7 IGAP SNP or the nonsynonymous SNP. ABCA7 is 
located in chromosome 19p13.3, and encodes a member of the superfamily of ATP-
binding cassette transporters. ABCA7 is expressed in microglia and oligodendrocytes 
[143] and potentially regulates lipid efflux and Aβ accumulation [144, 145]. Several 
SNPs in or close to ABCA7 were identified as AD risk alleles [41, 42, 68]. However, the 
impact of these SNPs is not yet well understood. 
 
Hypothesis 2: identified IGAP SNPs are regulatory SNPs 
In CELF1, we did not have sufficient evidence that the IGAP SNP rs10838725 and the 
coding SNP rs2293576 in strong LD with the IGAP SNP were associated with AD. 
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However, rs10838725 acted as cis-eQTL for MYBPC3 expression in the blood which was 
associated with AD. MYBPC3 is located on chromosome 11p11.2, and encodes cardiac 
myosin binding protein C expressed exclusively in heart muscle [146]. Huang et al. 
reported that the MYBPC3 and SPI1 were associated with the allele of rs1057233 in 
CELF1 (r2 = 0.17 and D’ = 0.97 with the IGAP SNP rs10838725 as shown in Table 1.2), 
and suggested that the association of MYBPC3 expression came from leaky transcription 
driven by the adjacent SPI1 expression [72].  
 
In addition to CR1, several IGAP SNPs were associated with gene expression in the 
brain. DLGAP1 and NETO1 expressions were regulated by the DSG2 IGAP SNP and 
were highly correlated with each other in FCTX. Interestingly, these genes were 
significantly under-expressed in MTG and SFG brain region of AD cases. The DSG2 
IGAP SNP also regulated KCNG2 expression which was under-expressed in MTG of AD 
cases as well, although it was not correlated with the DLGAP1 and NETO1 expressions. 
DLGAP1 is located in chromosome 18p11.31 more than 25Mb away from DSG2, and 
encodes disks large-associated protein 1 (also known as guanylate kinase- associated 
protein (GKAP)). NETO1 is located in chromosome 18q22.3 more than 40Mb away from 
DSG2 and encodes neuropilin and tolloid like 1. Both DLGAP1 and NETO1 are mainly 
expressed in neuros 
(http://web.stanford.edu/group/barres_lab/brainseqMariko/brainseq2.html) [132], and 
may be involved in the N-methyl-D-aspartate receptor-dependent synaptic plasticity [147, 
148]. KCNG2 located in chromosome 18q22.3, encodes a voltage-gated potassium 
channel subfamily G member 2, which is a potassium channel subunit. Potassium 
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channels are important regulatory proteins also associated with synaptic plasticity [149]. 
Synaptic plasticity is a fundamental property of the nervous system [150, 151]. Elevated 
Aβ levels induce synaptic dysfunction, and thus loss of synaptic proteins may contribute 
to AD progression. Although the role of DSG2 gene is unknown, this may imply that 
DSG2 is involved in brain functions including memory and learning. 
 
There are limitations to this study. We aggregated data from many rich resources that aid 
in establishing a confluence of related information; however, these datasets are 
heterogeneous and can exhibit biases from the respective study designs, analytic 
protocols, and participant pools. As per common but inexact convention, we identified 
genes as those closest to the identified IGAP SNP. Although our approach for identifying 
proxies and examining eQTL lessens the impact of this crude gene assignment, this still 
remains an open question in the field. 
 
In summary, investigating the functional role of the suspected and replicated SNPs 
associated with AD is an important next step to understanding the genetic contributions 
and the functional pathways linking AD developmental mechanisms. AD is a complex 
disease with a strong genetic component. However, much of the genetic contribution to 
AD remains unexplained. In future studies, we will need to investigate how RNA and 
protein levels as well as their interactions are affected the known genes. 
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Table 3.1. ADGC and CHARGE studies in ADSP 
Consortium Study 
ADGC  
 ACT 
 ADC 
 CHAP 
 EFIGA 
 GDF 
 MAP 
 MAYO 
 MAYO PD 
 MIA 
 MIRAGE 
 NCRAD 
 NIA-LOAD 
 RAS 
 ROS 
 TARCC 
 TOR 
 VAN 
 WHICAP 
  
CHARGE  
 ARIC 
 ASPS 
 CHS 
 ERF 
 FHS 
 RS 
ADGC = Alzheimer's Disease Genetic Consortium; CHARGE = Cohorts for Heart and 
Aging Research in Genomic Epidemiology; ADSP = Alzheimer's Disease Sequencing 
Project; ACT =Adult Changes in Thought; ADC = NIA Alzheimer Disease Centers; 
CHAP = Chicago Health and Aging Project; EFIGA = Estudio Familiar de la Influencia 
Genetica en Alzheimer; GDF = Genetic Differences; NIA-LOAD = National Institute on 
Aging (NIA) Late Onset Alzheimer's Disease Family Study; MAP = Memory and Aging 
Project; MAYO = Mayo Clinic; MAYO PD = Mayo PD; MIA = University of Miami; 
MIRAGE = Multi-Institutional Research in Alzheimer's Genetic Epidemiology; NCRAD 
= National Cell Repository for Alzheimer's Disease; RAS = University of Washington 
Families; ROS = Religious Orders Study; TARCC = Texas Alzheimer's Research and 
Care Consortium; TOR = University of Toronto; VAN = Vanderbilt University; 
WHICAP = Washington Heights-Inwood Columbia Aging Project; ARIC = 
Atherosclerosis Risk in Communities Study; ASPS = Austrian Stroke Prevention Study; 
CHS = Cardiovascular Health Study; ERF = Erasmus Rucphen Family; FHS = 
Framingham Heart Study; RS = Rotterdam Study  
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Table 3.2. Characteristics of the individual in ADSP 
Variable 
Overall 
n (%) 
AD cases 
n (%) 
AD controls 
n (%) 
ADSP (n = 10,468) 5,374 (51.3) 5,094 (48.7) 
 Sex    
  Male 4,380 (41.8) 2,313 (43.0) 2,067 (40.6) 
  Female 6,088 (58.2) 3,061 (57.0) 3,027 (59.4) 
 Age at the last visit or at death   
  65-69 570 (5.5) 537 (10.0) 33 (0.6) 
  70-74 1,127 (10.8) 1,062 (19.8) 65 (1.3) 
  75-79 1,355 (12.9) 1,153 (21.5) 202 (4.0) 
  80-84 2,650 (25.3) 1,092 (20.3) 1,558 (30.6) 
  84-90 3,139 (30.0) 896 (16.7) 2,243 (44.0) 
  90+ 1,627 (15.5) 634 (11.8) 993 (19.5) 
 APOE    
  -/- 7,476 (71.4) 3,140 (58.4) 4,336 (85.1) 
  -/ε4 2,900 (27.7) 2,159 (40.2) 741 (14.5) 
  ε4/ε4 91 (0.9) 75 (1.4) 17 (0.3) 
ADSP = Alzheimer's Disease Sequencing Project; APOE = apolipoprotein E 
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Table 3.3. Exonic single nucleotide polymorphism correlated with the IGAP SNP 
 IGAP SNP 
Closest 
Gene 
Exonic SNP  1000 Genomes EUR 
SNP ID Position Variant a Alleles b Gene  MAF r2 D’ 
Strong LD (r2 ≥ 0.8)        
 rs6656401 CR1 rs4844600 207,679,307 E60E G/A CR1  0.19 0.88 0.99 
   rs2296160 207,795,320 A2419T G/A CR1  0.18 0.84 0.93 
 rs9271192 HLA-DRB5 rs9270303 32,557,483 A13T C/T HLA-DRB1  0.25 0.92 0.99 
 rs1476679 ZCWPW1 rs2405442 99,971,313 L12L C/T PILRA  0.32 0.85 0.97 
   rs1859788 99,971,834 G78R G/A PILRA  0.32 0.85 0.97 
 rs9331896 CLU rs7982 27,462,481 H263H G/A CLU  0.39 0.90 0.97 
 rs10838725 CELF1 rs2293576 47,434,986 A191A G/A SLC39A13  0.31 0.84 0.99 
 rs983392 MS4A6A rs12453 59,945,745 L137L T/C MS4A6A  0.40 0.80 0.91 
 rs4147929 ABCA7 rs3752246 1,056,492 A1527G C/G ABCA7  0.19 0.97 1 
 rs3865444 CD33 rs12459419 51,728,477 A14V C/T CD33  0.31 1 1 
a The first amino acid is linked to major allele and the second one to minor allele. b Major/minor alleles 
IGAP = International Genomics of Alzheimer’s Project; SNP = single nucleotide polymorphism; MAF = minor allele frequency; LD= 
linkage disequilibrium; 1000 Genomes = 1000 Genomes Project Phase 3 in individuals of European ancestry 
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Table 3.3. (Continued) 
 IGAP SNP 
Closest 
Gene 
Exonic SNP  1000 Genomes EUR 
SNP ID Position Variant a Alleles b Gene  MAF r2 D’ 
Moderate LD (0.4 ≤ r2 < 0.8)        
 rs9271192 HLA-DRB5 rs2308759 32,549,596 V130V C/T HLA-DRB1  0.14 0.45 1 
   rs1049092 32,629,802 D201D G/A HLA-DQB1  0.40 0.51 0.97 
   rs1049086 32,629,904 D167D G/A HLA-DQB1  0.40 0.50 0.97 
 rs2718058 NME8 rs2722372 37,890,267 R43K G/A NME8  0.25 0.49 0.93 
   rs2598044 37,890,316 D59D C/T NME8  0.25 0.49 0.93 
 rs1476679 ZCWPW1 rs909152 100,175,473 G337G C/T LRCH4  0.31 0.53 0.75 
 rs10838725 CELF1 rs12286721 47,701,528 I671M A/C AGBL2  0.28 0.48 0.97 
 rs983392 MS4A6A rs7232 59,940,599 T213S T/A MS4A6A  0.36 0.68 0.92 
 rs8093731 DSG2 rs16961975 29,046,606 V509M G/A DSG3  0.012 0.51 0.75 
   rs61730311 29,049,138 R575W C/T DSG3  0.010 0.67 0.90 
 rs4147929 ABCA7 rs4147930 1,064,193 L1995L A/G ABCA7  0.28 0.56 1 
   rs4147934 1,065,018 S2045A T/G ABCA7  0.28 0.55 0.98 
   rs2074442 1,074,000 D275E T/A HMHA1  0.27 0.56 0.97 
   rs2074454 1,080,311 P603P C/G HMHA1  0.26 0.49 0.88 
   rs10404947 1,081,617 Q769Q G/A HMHA1  0.22 0.44 0.74 
 rs3865444 CD33 rs35112940 51,738,917 G304R G/A CD33  0.21 0.57 0.98 
a The first amino acid is linked to major allele and the second one to minor allele. 
IGAP = International Genomics of Alzheimer’s Project; SNP = single nucleotide polymorphism; MAF = minor allele frequency; LD= 
linkage disequilibrium; 1000 Genomes = 1000 Genomes Project Phase 3 in individuals of European ancestry 
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Table 3.4. Association results for exonic SNPs correlated with the IGAP SNPs 
IGAP SNP Closest gene 
Exonic SNP 
SNP ID Gene OR P-value 
Strong LD (r2 ≥ 0.8)     
 rs6656401 CR1 rs4844600 CR1 - - 
   rs2296160 CR1 1.11 7.47 × 10-3 
 rs9271192 HLA-DRB5 rs9270303 HLA-DRB1 1.16 1.68 × 10-4 
 rs1476679 ZCWPW1 rs2405442 PILRA 0.89 1.22 × 10-3 
   rs1859788 PILRA 0.89 1.22 × 10-3 
 rs9331896 CLU rs7982 CLU 0.90 1.30 × 10-3 
 rs10838725 CELF1 rs2293576 SLC39A13 1.08 0.030 
 rs983392 MS4A6A rs12453 MS4A6A 0.89 3.56 × 10-4 
 rs4147929 ABCA7 rs3752246 ABCA7 1.18 1.30 × 10-4 
 rs3865444 CD33 rs12459419 CD33 0.95 0.11 
       
Moderate LD (0.4 ≤ r2 < 0.8)     
 rs9271192 HLA-DRB5 rs2308759 HLA-DRB1 1.09 0.062 
   rs1049092 HLA-DQB1 1.12 7.29 × 10-4 
   rs1049086 HLA-DQB1 1.11 1.37 × 10-3 
 rs2718058 NME8 rs2722372 NME8 0.90 3.19 × 10-3 
   rs2598044 NME8 0.90 3.61 × 10-3 
 rs1476679 ZCWPW1 rs909152 LRCH4 0.97 0.33 
 rs10838725 CELF1 rs12286721 AGBL2 1.05 0.13 
 rs983392 MS4A6A rs7232 MS4A6A 0.87 3.53 × 10-5 
 rs8093731 DSG2 rs16961975 DSG3 1.21 0.23 
   rs61730311 DSG3 1.15 0.45 
 rs4147929 ABCA7 rs4147930 ABCA7 1.10 9.92 × 10-3 
   rs4147934 ABCA7 1.10 6.04 × 10
-3 
   rs2074442 HMHA1 1.08 0.045 
   rs2074454 HMHA1 1.09 0.019 
   rs10404947 HMHA1 1.07 0.086 
 rs3865444 CD33 rs35112940 CD33 0.98 0.67 
A bold p-value represents the statistical significance after FDR adjustment. 
IGAP = International Genomics of Alzheimer’s Project; SNP = single nucleotide 
polymorphism; ADSP = Alzheimer's Disease Sequencing Project; OR = odds ratio; LD= 
linkage disequilibrium 
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Table 3.5. Pathogenic nature of nonsynonymous single nucleotide polymorphism associated with AD 
 Exonic SNP Gene 
Major/minor 
allele 
Variant a SIFT PolyPhen-2 
Nonsynonymous     
 rs2296160 CR1 G/A A2419T Tolerated (0.39) Benign (0.0) 
 rs9270303 HLA-DRB1 C/T A13T Tolerated (1.0) Benign (0.0) 
 rs1859788 PILRA G/A G78R Tolerated (1.0) Benign (0.0) 
 rs3752246 ABCA7 C/G A1527G Tolerated (0.88) Benign (0.0) 
 rs7232 MS4A6A T/A T213S Deleterious (0.03) Possibly damaging (0.827) 
a The first amino acid is linked to major allele and the second one to minor allele, and the codon number is for the biggest isoform. 
SNP = single nucleotide polymorphism 
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Table 3.6. Significant cis- and trans-association of the IGAP SNPs with blood gene expressions in ADNI 
IGAP SNP Closest gene Probe set ID a Gene Cis or trans 
eQTL association  AD association 
β P-value b   P-value c 
rs1476679 ZCWPW1 11736388_a_at TRIM4 Cis -0.126 1.16 × 10-8  0.78 
  11760665_at ZKSCAN1 Cis 0.150 1.96 × 10-7  0.18 
  11722909_a_at GATS Cis 0.177 4.14 × 10-17  0.86 
  11730247_a_at PVRIG Cis 0.088 8.39 × 10-5  0.36 
  11743311_a_at PILRB Cis -0.113 1.20 × 10-8  0.28 
  11730023_s_at PILRB Cis -0.106 3.44 × 10-8  0.53 
  11730022_a_at PILRB Cis -0.129 5.41 × 10-8  0.68 
rs11771145 EPHA1 11755327_s_at LOC154761 Cis 0.110 5.11 × 10-6  0.59 
rs28834970 PTK2B 11761824_at NSAP11 Trans 0.028 8.78 × 10-5  1.00 
  11723344_at TRIM35 Cis -0.067 1.31 × 10-5  0.29 
  11720981_a_at PTK2B Cis 0.109 3.03 × 10-15  0.13 
  11720982_s_at PTK2B Cis 0.079 1.72 × 10-14  0.077 
  11720980_a_at PTK2B Cis 0.089 3.04 × 10-10  0.12 
rs10838725 CELF1 11725151_at MYBPC3 Cis 0.145 1.82 × 10-7  3.80 × 10-4 
rs983392 MS4A6A 11716846_a_at MS4A6A Cis -0.087 1.27 × 10-12  0.045 
  11732865_a_at MS4A4A Cis -0.178 2.69 × 10-6  0.70 
  11751570_a_at MS4A4A Cis -0.148 3.02 × 10-6  0.97 
rs8093731 DSG2 11735070_a_at GNAL Trans -0.317 9.65 × 10-6  0.35 
rs7274581 CASS4 11720252_s_at C20orf194 Trans -0.210 7.33 × 10-5  0.74 
  11723408_a_at MKKS Trans -0.130 5.03 × 10-5  0.85 
A bold p-value represents the statistical significance after FDR adjustment. 
a Probe set IDs on Affymetrix Human Genome U219 Array 
b P-values less than false discovery rate (FDR) adjusted significance level 
c P-values calculated by analysis of covariance with the outcome of gene expression and the predictor of AD status (normal/MCI/AD) 
IGAP = International Genomics of Alzheimer’s Project; SNP = single nucleotide polymorphism; eQTL = expression quantitative trait 
locus; ADNI = Alzheimer's Disease Neuroimaging Initiative  
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Table 3.7. Significant cis- and trans-association of the IGAP SNPs with brain gene expressions in NABEC and UKBEC 
 SNP ID 
Closest 
gene 
Probe set ID a 
Gene 
expression 
Cis or 
trans 
Brain 
region 
β P-value b 
NABEC       
 rs10792832 PICALM ILMN_1714980 MRGPRD Trans CRBLM 0.066 1.62 × 10-5 
 rs8093731 DSG2 ILMN_2380779 DLGAP1 Trans FCTX 0.848 4.87 × 10-10 
   ILMN_1783168 NETO1 Trans FCTX 0.757 1.66 × 10-6 
   ILMN_1780373 KCNG2 Trans CRBLM 0.408 6.76 × 10-5 
 rs7274581 CASS4 ILMN_1731948 PCK1 Trans CRBLM 0.241 7.29 × 10-6 
         
UKBEC       
 rs6656401 CR1 t2408244 COL9A2 Trans MEDU 0.152 3.50 × 10-6 
   t2434716 CERS2 Trans MEDU 0.284 1.87 × 10-6 
   t2437801 ARHGEF2 Trans MEDU 0.183 1.15 × 10-5 
   t2376299 CNTN2 Trans MEDU 0.297 5.59 × 10-6 
   t2376457 CDK18 Trans MEDU 0.323 9.83 × 10-6 
   t2377332 CR1,CR1L Cis AveALL 0.078 4.22 × 10-6 
      WHMT 0.172 6.55 × 10-7 
a Probe set IDs on HumanHT-12_v3 Expression BeadChips in NABEC, and on Affymetrix Exon 1.0 ST Arrays in UKBEC 
b P-values less than false discovery rate (FDR) adjusted significance level  
IGAP = International Genomics of Alzheimer’s Project; SNP = single nucleotide polymorphism; NABEC = North American Brain 
Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; FCTX = frontal cortex; CRBLM = cerebellum; 
MEDU = medulla; WHMT = white matter; AveALL = average of all 10 regions 
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Table 3.8. Associations between gene expressions identified in NABEC and UKBEC and AD status in GSE5281 dataset, entorhinal 
cortex (EC), hippocampus (HIPP), and medial temporal gyrus (MTG) 
Probe set ID a 
EC  HIP  MTG 
β P-value  β P-value  β P-value 
Identified in NABEC b        
 DLGAP1         
  206489_s_at -0.979 0.058  -1.511 0.010  -1.383 0.03 
  206490_at -0.320 0.31  -0.350 0.084  -1.266 1.04 × 10-3 
  210750_s_at 0.876 0.24  0.915 0.15  -0.348 0.56 
  235527_at -0.761 0.15  0.875 4.59 × 10-5  1.363 0.033 
 NETO1         
  1552736_a_at -0.787 0.10  0.009 0.97  -1.140 0.058 
  1552904_at -1.728 8.03 × 10-4  0.023 0.95  -1.400 0.027 
  1562713_a_at -1.742 0.024  -0.614 0.41  -1.993 6.86 × 10-4 
  236440_at -0.580 0.22  -0.744 0.064  -1.988 7.41 × 10-5 
 KCNG2         
  208550_x_at -0.413 0.26  0.431 0.21  -1.933 6.97 × 10-4 
 PCK1         
  208383_s_at 0.948 0.20  0.787 0.26  1.306 0.030 
A bold p-value represents the statistical significance after FDR adjustment. 
a Probe set IDs on Affymetrix U133 Plus 2.0 array 
b There is no MRGPRD expression data available. 
NABEC = North American Brain Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; EC = entorhinal 
cortex; HIPP = hippocampus (HIPP); MTG = medial temporal gyrus 
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Table 3.8. (Continued) 
Probe set ID a 
EC  HIP  MTG 
β P-value  β P-value  β P-value 
Identified in UKBEC         
 COL9A2         
  213622_at -0.384 0.32  0.502 0.37  1.031 0.021 
  232542_at 1.696 7.83 × 10-3  0.148 0.76  -0.577 0.32 
 CERS2         
  222212_s_at 0.744 3.63 × 10-3  -0.526 0.11  0.480 0.021 
 ARHGEF2         
  1554783_s_at -1.296 0.092  0.137 0.84  -0.942 0.17 
  207629_s_at -0.319 0.52  -0.390 0.33  -0.373 0.33 
  209435_s_at -0.920 1.79 × 10-6  0.246 0.16  0.058 0.77 
  235595_at 1.033 0.041  0.963 0.058  0.590 0.18 
 CNTN2         
  206970_at -0.993 0.11  -1.725 0.020  -0.460 0.46 
  230045_at 0.751 0.023  -0.550 0.20  -0.146 0.58 
 CDK18         
  214797_s_at -0.352 0.62  0.032 0.94  -0.152 0.78 
 CR1         
  206244_at -0.783 0.24  -1.259 0.013  -2.028 2.29 × 10-3 
  208488_s_at 0.732 0.33  0.151 0.80  -0.231 0.69 
  217484_at 0.840 0.069  0.457 0.35  0.717 0.15 
  244313_at 1.501 3.81 × 10-3  -0.099 0.86  -0.098 0.87 
A bold p-value represents the statistical significance after FDR adjustment. 
a Probe set IDs on Affymetrix U133 Plus 2.0 array 
NABEC = North American Brain Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; EC = entorhinal 
cortex; HIPP = hippocampus (HIPP); MTG = medial temporal gyrus 
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Table 3.9. Associations between gene expressions identified in NABEC and UKBEC and AD status in GSE5281 dataset, posterior 
cingulate (PC), superior frontal gyrus (SFG), and primary visual cortex (VCX) 
Probe set ID a 
PC  SFG  VCX 
β P-value  β P-value  β P-value 
Identified in NABEC b        
 DLGAP1         
  206489_s_at -1.449 0.012  -1.801 3.57 × 10-4  -0.647 0.20 
  206490_at -0.183 0.51  -1.229 3.20 × 10-3  -0.995 0.011 
  210750_s_at 1.027 0.094  -0.352 0.60  0.755 0.20 
  235527_at -0.722 0.040  -0.671 0.16  -0.937 0.024 
 NETO1         
  1552736_a_at -0.098 0.74  -1.591 6.53 × 10-4  -0.556 0.29 
  1552904_at -1.210 0.068  -0.740 0.061  -0.158 0.81 
  1562713_a_at -1.180 0.13  -2.066 1.10 × 10-3  -0.557 0.16 
  236440_at -1.029 5.19 × 10-3  -1.079 0.049  -0.404 0.29 
 KCNG2         
  208550_x_at 0.729 0.066  -1.089 0.024  0.965 0.017 
 PCK1         
  208383_s_at 0.906 0.28  -0.016 0.98  -0.470 0.48 
A bold p-value represents the statistical significance after FDR adjustment. 
a Probe set IDs on Affymetrix U133 Plus 2.0 array 
b There is no MRGPRD expression data available. 
NABEC = North American Brain Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; PC = posterior 
cingulate; SFG = superior frontal gyrus; VCX = primary visual cortex 
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Table 3.9. (Continued) 
Probe set ID a 
PC  SFG  VCX 
β P-value  β P-value  β P-value 
Identified in UKBEC        
 COL9A2         
  213622_at -0.029 0.97  -0.142 0.73  0.734 0.034 
  232542_at 0.948 0.16  0.121 0.84  -0.537 0.22 
 CERS2         
  222212_s_at -0.316 0.32  -0.275 0.33  0.567 0.031 
 ARHGEF2         
  1554783_s_at 0.910 0.21  -0.759 0.15  0.924 0.15 
  207629_s_at 0.185 0.69  -0.761 0.041  0.280 0.33 
  209435_s_at 0.461 3.20 × 10-4  -0.671 0.019  0.253 0.13 
  235595_at 2.245 1.02 × 10-3  0.172 0.73  0.400 0.33 
 CNTN2         
  206970_at -1.270 0.070  -1.402 0.011  0.284 0.56 
  230045_at -0.104 0.72  -0.135 0.74  0.006 0.98 
 CDK18         
  214797_s_at 0.714 0.18  -0.899 0.12  0.796 0.18 
 CR1         
  206244_at 1.336 0.082  -1.075 0.10  1.282 0.049 
  208488_s_at 0.332 0.52  -1.239 0.015  0.655 0.20 
  217484_at 0.688 0.24  -0.344 0.45  1.139 4.21 × 10-3 
  244313_at 0.780 0.14  0.299 0.61  1.248 0.01 
A bold p-value represents the statistical significance after FDR adjustment. 
a Probe set IDs on Affymetrix U133 Plus 2.0 array 
NABEC = North American Brain Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; PC = posterior 
cingulate; SFG = superior frontal gyrus; VCX = primary visual cortex 
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Table 3.10. Associations between gene expressions identified in NABEC and UKBEC and AD status in Allen Institute dataset 
Gene expression a 
FWM  HIP  PCx  TCx 
β P-value  β P-value  β P-value  β P-value 
Identified in NABEC b            
 DLGAP1 0.749 0.028  -0.109 0.056  -0.034 0.51  -0.036 0.38 
 NETO1 0.495 0.095  0.010 0.91  -0.033 0.55  -0.041 0.36 
 KCNG2 0.085 0.43  0.004 0.97  0.035 0.73  0.203 0.020 
 PCK1 0.380 0.25  0.248 0.36  0.533 0.04  0.368 0.096 
              
Identified in UKBEC            
 COL9A2 -0.262 0.12  0.016 0.88  0.062 0.62  0.232 0.041 
 CERS2 -0.087 0.55  0.094 0.11  -0.052 0.55  0.083 0.19 
 ARHGEF2 -0.088 0.27  -0.028 0.51  -0.021 0.59  0.112 1.98 × 10-3 
 CNTN2 -0.143 0.41  0.034 0.70  -0.086 0.42  0.219 0.011 
 CDK18 -0.218 0.22  0.063 0.53  0.059 0.59  0.263 2.41 × 10-3 
 CR1 0.151 0.46  0.128 0.47  0.005 0.97  0.045 0.78 
A bold p-value represents the statistical significance after FDR adjustment. 
a RNA sequencing on Illumina HighSeq 2500 
b MRGPRD expression was removed because of little expressions. 
NABEC = North American Brain Expression Consortium; UKBEC = United Kingdom Brain Expression Consortium; FWM = white 
matter; HIPP = hippocampus; PCx = parietal cortex; TCx = temporal cortex 
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Figure 3.1. Possible causal relationships between single nucleotide polymorphisms (SNPs), mRNA, and phenotype.  
IGAP = International Genomics of Alzheimer’s Project; eQTL = expression quantitative trait locus 
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Figure 3.2. Flow diagram of the subjects included in the analyses. 
ADSP = Alzheimer's Disease Sequencing Project 
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Figure 3.3. Correlation between gene expressions potentially regulated by IGAP SNPs in NABEC  
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Figure 3.4. Correlation between gene expressions potentially regulated by CR1 SNPs in UKBEC
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Figure 3.5. Plot for the associations of the CR1 SNPs with the CR1 expression in the 
average of 10 brain regions of UKBEC. The outlined square, circle, and triangle indicate 
the synonymous SNP rs4844600, the IGAP SNP rs6656401, and the nonsynonymous 
SNP rs2296160, respectively. 
 
SNP = single nucleotide polymorphism; ADSP = Alzheimer's Disease Sequencing 
Project; UKBEC = United Kingdom Brain Expression Consortium 
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CHAPTER FOUR 
Identifying regions harboring Alzheimer’s disease related rare variants using scan-
statistic-based analysis of exome sequencing data 
 
Abstract  
Recent advances in sequencing technologies have allowed the move toward 
comprehensive genome-wide approaches, enabling more accurate genotyping of rare 
variants. To date, several studies have succeeded in identifying rare variants associated 
with Alzheimer’s disease (AD), yielding protective or risk effects. We applied a scan-
statistic-based approach and developed an approach to construct optimized windows 
within a gene to find meaningful clusters harboring risk or protective rare variants for 
AD. Data in this study came from the Alzheimer's Disease Sequencing Project (ADSP) 
comprising 18 studies from the Alzheimer's Disease Genetic Consortium (ADGC), and 6 
studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) Consortium. Of the 10,031 subjects included in this study, 5,142 (51.3%) 
were diagnosed as AD. We evaluated the scan statistics with different settings in TREM2 
and TOMM40 as highly-replicated positive controls. We obtained very similar scan 
statistic values when we specified the whole genome and chromosome as a large genetic 
region. Our optimized window approach captured almost the entire gene in TREM2 and 
the single variant in TOMM40 as a meaningful cluster. Applying the optimized window 
approach in all genes, we detected clusters harboring risk or protective variants for AD 
including MUC6, NXNL1, and BCAM. As more NGS data become available, it is of great 
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interest to see whether these findings are replicated in other cohorts of European ancestry 
as well as different populations. 
 
Introduction 
Over the past decade, genome-wide association studies (GWAS) have identified common 
risk loci for Alzheimer’s disease (AD). It is well known that the ε4 allele of 
apolipoprotein E (APOE) is the major genetic risk factor for late onset of AD. In addition 
to APOE, GWAS have detected and replicated several single nucleotide polymorphisms 
(SNPs) that are associated with susceptibility of AD, including in or close to CR1, BIN1, 
INPP5D, MEF2C, CD2AP, NME8, EPHA1, PTK2B, PICALM, SORL1, FERMT2, 
SLC24A4-RIN3, DSG2, CASS4, HLA-DRB5-DBR1, CLU, MS4A6A, ABCA7, CD33, 
ZCWPW1, and CELF1 [41-45].  
 
Rare variants have become a focus in the recent past. Although GWAS have been 
successful in interrogating genetic variants for association with disease, GWAS are 
performed under the “common disease – common variant” hypothesis positing that 
common traits are caused by the combination of common variants with a small to 
moderate effect [58]. GWAS rely on genotyping preselected SNPs and imputing 
ungenotyped variants based on local linkage disequilibrium (LD) of a set of some 
haplotypes from reference population. Imputation approaches have continually improved 
and are quite accurate for common variants [59, 60] but are not as reliable for rare 
variants [61]. Therefore, imputed rare variants are typically removed from GWAS 
analysis. Although GWAS for common variants have revealed numerous susceptibility 
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variants for common diseases, much of the genetic contribution to common diseases 
remains unexplained – the so called ‘missing heritability’ problem [152, 153]. One 
possible explanation of this missing heritability is that rare variants may account for 
additional disease variability [153, 154].  
 
Recent advances in sequencing technologies have allowed to move toward 
comprehensive genome-wide approaches, enabling to accurately genotype rare variants 
generally defined as a variant with minor allele frequency (MAF) < 1-5%. These next-
generation sequencing (NGS) technologies have the potential to improve our 
understanding the role of both common and rare variants in the underlying biological 
mechanisms of developing a disease. Whole-exome sequencing (WES) and whole-
genome sequencing (WGS) are ideal approaches to identify novel variants and genes 
associated with complex traits.  
 
To date, several studies have reported rare variants associated with AD, yielding 
protective or risk effects. Jonsson et al. found that a rare missense variant in TREM2 -- 
rs75932628 producing an amino acid substitution (arginine to histidine at codon 47) -- 
was associated with the risk of AD [155]. Concurrently, Guerreiro et al. confirmed that 
rs75932628 was the most associated variant with AD in TREM2 [156]. This variant is 
considered the first NGS-based finding of a novel rare variant associated with AD risk. 
Since then, several rare variants have been reported as risk or protective factors for AD, 
including in or near BIN1, UNC5C, TREM2, CD2AP, AKAP9, EPHA1, SORL1, TM2D3, 
PLCG2, ABI3, PLD3, and ABCA7 (Table 4.1).  
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Most coding variants, however, are very rare, and thus an extremely large sample size is 
required to identify a single variant associated with a disease. There are significant 
computational and statistical challenges for these sequencing studies. Traditional single-
variant-based association tests are underpowered to detect rare variant associations unless 
sample size and/or effect size is very large [62]. Instead of testing single variant 
individually, more powerful and computationally efficient approaches for aggregating the 
effects of rare variants have become a standard approach for association testing. Many 
such approaches for testing association between rare variants within a pre-specified 
region and a disease have been proposed. A recently-proposed scan-statistic-based test 
can be used to detect the location of rare variant clusters influencing a disease. The scan-
statistic-based test was introduced into human genetics by Hoh et al [65] to locate 
susceptibility genes. Ionita-Laza et al. adapted this test to identify clusters of rare disease 
risk variants based on a likelihood ratio under a Bernoulli model as proposed by 
Kulldorff [66, 67]. 
 
Variants within a functional protein-coding domain may be located in close proximity 
and may play a similar role in genetic mechanisms of a disease. Unlike association tests 
or other cluster detection analyses, the scan-statistic-based test [67] adopted in this work 
can both detect the location of clusters and examine the association against the null 
hypothesis that variants within a certain scan window are equally likely to confer AD risk 
compared to those outside the window. This approach is powerful when there are clusters 
of disease-related variants with the same direction of association within a selected 
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region/window [67]. In this study, we applied the scan-statistic-based approach and 
optimized windows within a gene to find meaningful clusters harboring risk or protective 
rare variants for AD.  
 
Material and methods 
Study subjects 
Data in this study came from the Alzheimer's Disease Sequencing Project (ADSP) 
comprising 18 studies from the Alzheimer's Disease Genetic Consortium (ADGC), and 6 
studies from the Cohorts for Heart and Aging Research in Genomic Epidemiology 
(CHARGE) Consortium. The ADSP consists of a smaller family-based study and a case-
control study of unrelated subjects. In this study, we used the case-control study dataset 
containing whole exome sequencing (WES) data on 10,913 subjects (Table 4.2). Of the 
10,913 subjects in WES data, 10,468 subjects who had the AD diagnosis available and 
who were 65 years or older at the last visit or at death were included in a principal 
component analysis (PCA) to identify ethnic outliers. PCA was performed in PLINK 
v1.90a [82] using a linkage disequilibrium (LD) pruned subset of markers (pairwise r2 < 
0.2) from these data and 1000 Genomes Project Phase 3 (1000 Genomes) [84] data after 
removing symmetric SNPs and flipping SNPs discordant for DNA strands between 
ADSP WES and 1000 Genomes data. We then plotted the first and second principal 
components (PCs) for each individual (n = 10,468 from ADSP WES and n = 2,504 from 
1000 Genomes) using the ggplot2 R package (version 2.2.0) [85] in R (version 3.4.1; 
http://www.r-project.org). Based on the PC plot, 437 subjects were removed as ethnic 
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outliers (Figure 4.1 and Figure 4.2). We considered individuals who were marked as 
prevalent or incident AD at year 0 AD cases. 
 
ADSP WES data 
We obtained the public access WES data containing biallelic single nucleotide variants 
and insertion/deletion (indels) genotypes from ADSP in the unrelated sample set. The 
WES data was generated by applying a quality control protocol designed by the ADSP 
Quality Control Working Group, removing low-quality variants and samples (see the 
details in Supplementary Method 1). 
 
Statistical analysis 
The likelihood ratio (LR) statistic for the Bernoulli model from the scan-statistic-based 
test is defined as: 
𝐿𝑅𝑊 = {
(
?̂?𝑊
?̂?𝐺
)
𝑦𝑊
(
1 − ?̂?𝑊
1 − ?̂?𝐺
)
𝑛𝑊−𝑦𝑊
(
?̂?𝑊
?̂?𝐺
)
𝑦𝐺−𝑦𝑊
(
1 − ?̂?𝑊
1 − ?̂?𝐺
)
𝑛𝐺−𝑛𝑊−(𝑦𝐺−𝑦𝑊)
 if ?̂?𝑊 > ?̂?𝑊
1 otherwise
 
where  
𝑦𝑊 = ∑ 𝑦𝑖
𝑖∈𝑊
, 𝑦𝐺 = ∑ 𝑦𝑖
𝑖∈𝐺
, 𝑛𝑊 = ∑ 𝑛𝑖
𝑖∈𝑊
, 𝑛𝐺 = ∑ 𝑛𝑖
𝑖∈𝐺
 
?̂?𝑊 =
𝑦𝑊
𝑛𝑊
, ?̂?𝑊 =
𝑦𝐺 − 𝑦𝑊
𝑛𝐺 − 𝑛𝑊
, ?̂?𝐺 =
𝑦𝐺
𝑛𝐺
 
𝑊 is a window with fixed size 𝑤 defined by the number of base pairs, 𝐺 is a large genetic 
region of interest, and 𝑦𝑖 and 𝑛𝑖 are the numbers of AD cases and total subjects carrying 
the 𝑖th rare variant, respectively [67]. The window 𝑊 with the highest 𝐿𝑅𝑊 is the most 
likely region to harbor a cluster of disease-associated variants.  
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The definitions of the large genetic region 𝐺 and the window 𝑊 are flexible. The power 
of the test primarily depends on the total number of risk variants in the entire genetic 
region  𝐺, the expected number of risk variants in the cluster, and the ratio of the 
probabilities of being risk variants inside and outside of the cluster [157]. Other factor 
influencing the power is how well the scanning window size matches the true cluster size. 
The scan statistics are sensitive for the chosen scanning window. A cluster within a 10 kb 
sized region, for example, may not be detected by two consecutive scanning windows of 
5 kb (i.e., the cluster is split by two windows). A sliding window approach (i.e., partially 
overlapping windows) may be one of the solutions for this problem. Another issue is that 
the power may decrease when the true cluster window size is larger relative to the entire 
region and when scanning window size is too large compared to the true cluster size [67]. 
Ideally, one would hope to define a scanning window so that it is matched to the true 
cluster harboring variants related to disease.  
 
We first compared the likelihood ratio (LR) statistic between different settings for a large 
genetic region 𝐺, a fixed window size 𝑊, and a sliding window size using a sliding 
window approach. We used TREM2 (located on chromosome 6p21.1) and TOMM40 
(located on chromosome 19q13.32) as highly-replicated positive controls to evaluate the 
scan statistics for risk and protective effects. Using Fisher’s exact test as implemented in 
PLINK v1.90a [82], we preliminarily confirmed that there was a significant variant in 
each of TREM2 and TOMM40 based on the false discovery rate (FDR)-adjusted p-value 
(i.e., q-value) < 0.05 defined as a significance level (Table 4.3). The variant rs75932628 
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(R47H, position: 41,129,252) in TREM2 was a significant risk rare variant for AD, 
showing a MAF of 0.94% in AD cases and 0.21% in controls. The odds ratio (OR) was 
4.41 and p-value was 4.30 × 10-12. On the other hand, the variant rs1160983 (S183S, 
position: 45,397,229) in TOMM40 had a protective effect with a MAF of 1.80% in AD 
cases and 4.34% in controls (OR = 0.39 and p-value = 2.12 × 10-21). TOMM40 is close to 
the APOE locus and the variant was in LD with APOE ε2 known as a protective factor (r2 
= 0.35 and D’ = 0.95).  
 
We tried to find optimized windows in TREM2 and TOMM40 by maximizing 𝐿𝑅𝑊 under 
the difference genetic region 𝐺 settings. In addition to these positive control genes, we 
applied the optimized window approach in all genes to identify regions that presumably 
target AD associated loci (see the details in Supplementary Method 2). We then evaluated 
the optimized windows using the burden test and sequence-kernel association test 
(SKAT) for the optimized windows (Supplementary Method 3) [63, 64]. The SKAT is 
powerful when both risk and protective variants are mixed and when a small proportion 
of variants are causal, whereas the burden test is more powerful than SKAT when most of 
the variants are causal and have the same direction of effect [63]. We used these 
properties to confirm whether the optimized windows successfully captured a cluster 
harboring risk or protective rare variants for AD. 
 
In all analyses above, we assumed a dominant mode of inheritance (MOI), and defined a 
rare variant as a variant of MAF < 0.05. We removed variants with a minor allele count 
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(MAC) < 5. Variants were assigned to genes based on their physical positions at the 
UCSC Genome Browser GRCh37/hg19 human assembly (https://genome.ucsc.edu/) [87]. 
 
Results 
Of the 10,031 subjects included in this study, 5,142 (51.3%) were diagnosed as AD. 
There were more females than males in both AD cases and controls. The majority of 
controls were aged 80 years or older and had no APOE ε4 alleles (Table 4.4). 
 
Scan-statistic-based analysis by a sliding window approach in TREM2 and TOMM40 
Table 4.5 shows the log 𝐿𝑅𝑊s for each window determined by a sliding window 
approach with several different settings in TREM2 (risk effect) and TOMM40 (protective 
effect). In both TREM2 and TOMM40, the log 𝐿𝑅𝑊s were very similar when the large 
genetic region 𝐺 was the whole genome or entire chromosome (6 and 19). When the large 
genetic region 𝐺 was the band level (6p21.1 and 19q13.32), the log 𝐿𝑅𝑊s were a little bit 
smaller than those for the whole genome and entire chromosome specified as 𝐺. The 
largest log 𝐿𝑅𝑊 (log 𝐿𝑅𝑊 ≈ 31) in TREM2 was obtained with the 5kb fixed and 2.5 kb 
sliding window sizes (41,125,156 - 41,130,156) and the 10kb fixed and 5kb sliding 
window sizes (41,120,156 - 41,130,156 and 41,125,156 - 41,135,156). From these 
results, we expected that a meaningful cluster would exist in 41,125,156 - 41,130,156. On 
the other hand, the setting with the 10kb fixed and 5kb sliding window sizes produced 
less log 𝐿𝑅𝑊 than other two window settings in TOMM40, implying that an interesting 
cluster would be in 45,395,468 - 45,397,468.  
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Scan-statistic-based analysis by an optimized window approach in TREM2 and TOMM40 
We optimized windows with each large genetic region 𝐺 in TREM2 and TOMM40 (Table 
4.6). As expected above, we detected the optimized window 41,126,655 - 41,129,252 in 
TREM2 existing within 41,125,156 - 41,130,156 and containing rs75932628 (R47H, 
position: 41,129,252), whichever large genetic region 𝐺 was specified. In TOMM40, the 
optimized window contained the associated single variant rs1160983 (S183S, position: 
45,397,229) that was located within 45,395,468 - 45,397,468 detected by the sliding 
window approach. 
 
Genome-widely scan-statistic-based analysis by an optimized window approach 
We applied the optimized window approach for all genes to identify clusters harboring 
risk or protective variants associated with AD (Figure 4.3). Top 10 genes with large 
log 𝐿𝑅𝑊 for each risk and protective effects were displayed in Table 4.7. Besides TREM2 
and TOMM40, the optimized windows in MUC6, NXNL1, and BCAM had larger log 𝐿𝑅𝑊 
than that in TREM2, and the optimized windows in MUC6, CADPS2, TYRO3, ADM, 
BCAM, CBLC, and LNP1 captured the variants significantly associated with AD in the 
single-variant-based analysis (Table 4.3). For MUC6, we detected two optimized 
windows, one with a cluster of risk variants and the other with protective variants, both of 
which had larger log 𝐿𝑅𝑊 than that in TREM2. The risk region 1,018,274 - 1,018,379 
contained 4 risk variants including two significant variants rs202193006 (P1485S, 
position: 1,018,348) and rs765785447 (A1474A, position: 1,018,379). Similarly, the 
protective region 1,016,800 - 1,017,015 contained 9 protective variants including the 
significant variant rs373231068 (P1971L, position: 1,016,889) (Table 4.8). For NXNL1, 
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the optimized window 17,565,477 - 17,566,489 were detected, harboring 4 risk rare 
variants with relatively high effect sizes, although these variants did not reach the FDR-
adjusted significance level (Table 4.8). The optimized protective window 45,312,432 - 
45,316,606 in BCAM was observed including two significant protective variants; 
rs28399653 (R77H, position: 45,315,445) and rs28399654 (V196I, position: 45,316,588) 
(Table 4.8). 
 
Discussion 
Based on the assumption that variants located in close proximity within a functional 
protein-coding domain play a similar role in increased or decreased disease susceptibility, 
we identified clusters of rare variants using the scan-statistic-based analysis with an 
optimized window approach. First, we evaluated the scan statistics of TREM2 and 
TOMM40 with different settings for a large genetic region 𝐺, a fixed window size 𝑊, and 
a sliding window size by a sliding window approach. We obtained very similar log 𝐿𝑅𝑊 
values when we specified the whole genome and chromosome as a large genetic region 
𝐺. This may indicate that the scan statistics are comparable between windows in different 
large genetic regions if the 𝐺 is large enough. Second, we optimized windows in the 
scan-statistic-based analysis. Ideally, it would be the best that an optimized window 
covers an entire gene if the gene itself affects a disease and captures one single variant if 
only the variant within the gene is significant. Our optimized window approach 
successfully identified the gene and the single variant in TREM2 and TOMM40, 
respectively. Of the 9 variants existing in the TREM2 gene region in the analysis, 8 
variants were contained in the optimized window. In addition, the p-value from the 
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burden test was smaller than that from SKAT as shown in Table 4.7. These may indicate 
that this optimized window successfully captured variants with the same direction of 
effect, and the entire TREM2 gene is associated with AD susceptibility as consistent to 
the previous report [158]. On the other hand, only one protective variant in TOMM40 was 
identified by the optimized window approach. There existed 3 variants in the TOMM40 
gene region. One was insignificant (OR = 0.71 and p-value = 0.71) and the other was 
rather risk (OR = 8.1 and p-value = 7.70 × 10-4).  
 
Applying the optimized window approach in all genes, we detected two regions in 
MUC6; 1,018,274 - 1,018,379 with a risk effect and 1,016,800 - 1,017,015 with a 
protective effect, both of which were larger log 𝐿𝑅𝑊 than TREM2. That is, risk and 
protective clusters coexist in MUC6. If a region has heterogeneity effect (i.e., including 
both risk and protective variant), the sliding window approach may not be able to detect 
regions unless proper window sizes are specified. The optimized window approach 
demonstrated that there exists two interesting regions in MUC6; one with a cluster of risk 
variants including two significant variants and the other with protective variants 
including one significant variant. The optimized window approach also detected the 
cluster in NXNL1 that captured 4 adjacent risk variants which are in strong LD with each 
other (r2 = 0.87 to 0.98 and D’ = 0.99 to 1). Although these variants were not shown to be 
significantly associated with AD in the single-variant-based test, the log 𝐿𝑅𝑊 of the 
optimized region was larger than that in TREM2, indicating that there is a cluster of 
disease risk variants within this region. The optimized window in BCAM was relatively 
large (the length was about 4kb) that captured 9 variants including two significant 
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protective variants. BCAM is located close to the APOE locus. The pairwise LD values 
were r2 = 0.09 and D’ = 0.46 between two significant protective variants and APOE ε2. 
Thus, the protective effect of BCAM may come from the APOE ε2 protective impact on 
AD as well as TOMM40. 
 
In recent years, the importance of TREM2 has been highlighted due to increased risk for 
AD. Consistent with previous studies [155, 156, 159, 160], the missense variant 
rs75932628 (R47H) in TREM2 was detected as a risk variant of AD in the single-variant-
based analysis. TREM2 located on chromosome 6p21.1 encodes a transmembrane 
receptor primarily expressed in microglia [161, 162], and has been shown to suppress 
inflammatory responses [163]. We optimized a window in which there were 8 risk 
variants with a relatively large effect size, all of which were missense variants except 
rs144250872 (L133L). The two variants rs2234253 (T96K) and rs2234256 (L211P) were 
in perfect LD with each other. The variant rs2234255 (H157Y) had the largest estimated 
OR (OR = 10.48, p-value = 6.50×10-3), showing a MAF of 0.11% in AD cases and 0.01% 
in controls. 
 
The association of rs75932628 (R47H) was replicated in many studies for individuals of 
European ancestry [158, 164-167], while other studies failed to replicate this association 
in East Asian and African American populations [168-171]. The association of the 
variant rs2234255 (H157Y) was found in the study of the Han Chinese [172] but not of 
European populations so far. Also, the variant rs2234256 (L211P) was identified in 
African American [171]. These disparities may be raised because of high variabilities of 
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MAF in the rare variants among different populations. According to Exome Aggregation 
Consortium (ExAC) data, for example, the MAFs are 0.26% in European, 0.088% in 
African American, and 0% in East Asian for rs75932628 (R47H), 0.0030% in European, 
0.059% in African American, and 0.20% in East Asian for rs2234255 (H157Y), and 
0.096% in European, 12.8% in African American, and 0.15% in East Asian for 
rs2234256 (L211P) [173]. Since we extracted individuals of European ancestry based on 
PCs in this study, there may not be enough power to detect rs2234255 (H157Y) in the 
single-variant-based analysis, although the effect size was large. We did identify the 
genetic region (i.e., 41,126,655 - 41,129,252) using the scan-statistic-based analysis with 
an optimized window approach in which potential risk variants previously identified 
across various populations were harbored.  
 
Using the large WES dataset derived from multiple research centers, we demonstrated the 
practicability of the optimized window approach in the scan-statistic-based analysis to 
detect a single variant and a cluster harboring risk or protective variants for AD. We 
identified several candidate genes exhibiting risk for AD and others playing a protective 
role using the optimized window approach. Our results strongly suggest the need for 
more investigation for these novel genes. As more NGS data become available, it is of 
great interest to see whether these findings are replicated in other cohorts of European 
ancestry as well as different populations. We also plan in future studies to examine how 
these mutations change the protein structure and function, and/or whether transgenic mice 
with these mutations exhibit AD-related pathogenesis. 
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Table 4.1. Summary of the major findings in rare variants associated with late-onset 
Alzheimer’s disease 
Gene Chr SNV Position Variant Reference 
BIN1 2 rs138047593 127,808,046 K358R [174] 
UNC5C 4 rs137875858 96,091,431 T835M [175] 
TREM2 6 rs143332484 41,129,207 R62H [158, 176] 
  rs75932628 41,129,252 R47H [155, 156] 
CD2AP 6 rs116754410 47,591,941 K633R [174] 
AKAP9 7 rs144662445 91,709,085 I2546M [177] 
  rs149979685 91,732,110 S3767L [177] 
EPHA1 7 rs202178565 143,095,499 P460L [174] 
SORL1 11 rs117260922 121,367,627 E270K [178] 
  rs143571823 121,429,476 T947M [178] 
TM2D3 15 rs139709573 102,186,966 P155L [179] 
PLCG2 16 rs72824905 81,942,028 P522R [176] 
ABI3 17 rs616338 47,297,297 S209F [176] 
PLD3 19 rs145999145 40,877,595 V232M [180] 
ABCA7 19 rs72973581 1,043,103 G215S [74] 
  rs770510230 1,058,154 E1679X [174] 
Chr = chromosome; SNV = single nucleotide variant 
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Table 4.2. Number of cases/controls and age range in each case-control study of ADSP 
Consortium Study Cases  Controls 
  n Age range  n Age range 
ADGC  4,966 40-99+  3,209 42-99+ 
 ACT 273 69-89  996 68-89 
 ADC 2,417 60-90+  839 64-90+ 
 CHAP 27 68-90+  204 78-90+ 
 EFIGA 160 59-90+  171 42-90+ 
 GDF 111 59-90+  96 77-90+ 
 NIA-LOAD 364 37-90+  111 78-90+ 
 MAP 132 71-90+  283 72-90+ 
 MAYO 250 60-87  99 78-90+ 
 MAYO PD 181 59-89  14 79-90+ 
 MIA 316 56-88  15 78-89 
 MIRAGE 0 -  20 74-90+ 
 NCRAD 160 58-90+  0 - 
 RAS 46 56-88  0 - 
 ROS 144 63-90+  207 67-90+ 
 TARCC 132 60-90+  12 80-89 
 TOR 9 40-84  0 - 
 VAN 210 60-90+  26 79-90+ 
 WHICAP 34 73-90+  116 78-90+ 
       
CHARGE  805 60-99+  1,927 61-99+ 
 ARIC 39 67-89  18 77-85 
 ASPS 121 60-89  5 78-86 
 CHS 251 68-90+  583 76-90+ 
 ERF 45 60-88  0 - 
 FHS 126 65-90+  455 61-90+ 
 RS 223 61-90+  866 76-90+ 
ADSP = Alzheimer's Disease Sequencing Project; ACT =Adult Changes in Thought; 
ADC = NIA Alzheimer Disease Centers; CHAP = Chicago Health and Aging Project; 
EFIGA = Estudio Familiar de la Influencia Genetica en Alzheimer; GDF = Genetic 
Differences; NIA-LOAD = National Institute on Aging (NIA) Late Onset Alzheimer's 
Disease Family Study; MAP = Memory and Aging Project; MAYO = Mayo Clinic; 
MAYO PD = Mayo PD; MIA = University of Miami; MIRAGE = Multi-Institutional 
Research in Alzheimer's Genetic Epidemiology; NCRAD = National Cell Repository for 
Alzheimer's Disease; RAS = University of Washington Families; ROS = Religious 
Orders Study; TARCC = Texas Alzheimer's Research and Care Consortium; TOR = 
University of Toronto; VAN = Vanderbilt University; WHICAP = Washington Heights-
Inwood Columbia Aging Project; ARIC = Atherosclerosis Risk in Communities Study; 
ASPS = Austrian Stroke Prevention Study; CHS = Cardiovascular Health Study; ERF = 
Erasmus Rucphen Family; FHS = Framingham Heart Study; RS = Rotterdam Study 
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Table 4.3. Significantly associated rare coding variants with Alzheimer’s disease assuming a dominant mode of inheritance 
Chr SNV ID Position Gene Alleles a 
MAF (%) 
 No. of subjects 
with minor allele OR P-value b Variant 
Cases Controls  Cases Controls 
3 rs9844083 100,170,628 LNP1 A/G 0.33 0.97  28 76 0.33 1.59×10-7 Q74Q 
6 rs75932628 41,129,252 TREM2 C/T 0.94 0.21  96 21 4.41 4.30×10-12 R47H 
7 rs746999306 122,303,575 CADPS2 A/C 0.35 0.03  35 3 11.31 7.49×10-8 C168G 
11 rs373231068 1,016,889 MUC6 G/A 2.26 4.73  194 380 0.45 4.97×10-19 P1971L 
11 rs202193006 1,018,348 MUC6 G/A 4.38 2.29  434 219 2.00 1.16×10-16 P1485S 
11 rs765785447 1,018,379 MUC6 G/C 3.59 1.90  359 182 1.96 1.41×10-13 A1474A 
11 rs764691516 10,327,875 ADM G/C 0.97 0.32  87 29 3.08 3.10×10-8 R14P 
15 rs149022093 41,862,356 TYRO3 T/C 2.25 1.12  188 92 2.05 1.18×10-8 1382+2T>C 
19 rs3208856 45,296,806 CBLC C/T 2.68 4.15  272 392 0.64 3.35×10-8 H405Y 
19 rs28399653 45,315,445 BCAM G/A 2.47 3.90  249 369 0.62 1.45×10-8 R77H 
19 rs28399654 45,316,588 BCAM G/A 2.45 4.02  248 383 0.60 5.75×10-10 V196I 
19 rs1160983 45,397,229 TOMM40 G/A 1.80 4.34  140 340 0.39 2.12×10-21 S183S 
a Major/minor alleles 
b P-values were calculated by Fisher’s exact test and displayed if significant based on false discovery rate (FDR) adjusted p-value < 
0.05. 
Chr = chromosome; SNV= single nucleotide variant; MAF = minor allele frequency; OR = odds ratio 
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Table 4.4. Characteristics of ADSP study subjects (n = 10,031) 
Variable 
AD cases (n = 5,142)  AD controls (n = 4,889) 
n %  n % 
Sex      
 Male 2,226 43.3  1,995 40.8 
 Female 2,916 56.7  2,894 59.2 
Age a      
 65 - 69 506 9.8  12 0.2 
 70 - 74 1,008 19.6  29 0.6 
 75 - 79 1,105 21.5  169 3.5 
 80 - 84 1,041 20.2  1,510 30.9 
 85 - 89 866 16.8  2,197 55.9 
 90 + 616 12.0  972 19.9 
APOE      
 - / - 3,001 58.4  4,189 85.7 
 ε4 / - 2,068 40.2  683 14.0 
 ε4 / ε4 73 1.4  17 0.3 
a Age at the last visit or at death 
ADSP = Alzheimer's Disease Sequencing Project 
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Table 4.5. Scan-statistic (logLRw) for windows determined by a sliding window approach in several different settings, TREM2 and 
TOMM40 
 
Gene 
Window size  Window position 
G logLRw 
 Fixed Sliding  Start End 
Risk effect    
 TREM2 2kb 1kb  41,128,156 41,130,156 Genome 25.42 
       Chromosome 6 25.43 
       Band 6p21.1 24.19 
     41,129,156 41,131,156 Genome 20.27 
       Chromosome 6 20.27 
       Band 6p21.1 19.24 
  5kb 2.5kb  41,125,156 41,130,156 Genome 31.02 
       Chromosome 6 31.03 
       Band 6p21.1 29.57 
     41,127,656 41,132,656 Genome 25.42 
       Chromosome 6 25.43 
       Band 6p21.1 24.19 
  10kb 5kb  41,120,156 41,130,156 Genome 31.01 
       Chromosome 6 31.02 
       Band 6p21.1 29.55 
     41,125,156 41,135,156 Genome 31.02 
       Chromosome 6 31.03 
       Band 6p21.1 29.57 
logLRw = log likelihood ratio for the window  
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Table 4.5. (Continued) 
 
Gene 
Window size  Window position 
G logLRw 
 Fixed Sliding  Start End 
Protective effect    
 TOMM40 2kb 1kb  45,395,468 45,397,468 Genome 48.43 
       Chromosome 19 48.13 
       Band 19q13.32 44.85 
     45,396,468 45,398,468 Genome 48.43 
       Chromosome 19 48.13 
       Band 19q13.32 44.85 
  5kb 2.5kb  45,393,968 45,398,968 Genome 48.43 
       Chromosome 19 48.13 
       Band 19q13.32 44.85 
     45,396,468 45,401,468 Genome 48.43 
       Chromosome 19 48.13 
       Band 19q13.32 44.85 
  10kb 5kb  45,391,468 45,401,468 Genome 38.37 
       Chromosome 19 38.06 
       Band 19q13.32 34.64 
     45,396,468 45,406,468 Genome 40.10 
       Chromosome 19 39.82 
       Band 19q13.32 36.74 
logLRw = log likelihood ratio for the window 
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Table 4.6. Scan-statistic (logLRw) for windows determined by an optimized window 
approach in each large genetic region, TREM2 and TOMM40 
Gene 
Optimized window 
G logLRw 
Start End 
Risk effect     
 TREM2 41,126,655 41,129,252 Genome 31.19 
  41,126,655 41,129,252 Chromosome 6 31.20 
  41,126,655 41,129,252 Band 6p21.1 29.75 
Protective effect     
 TOMM40 45,397,229 45,397,229 Genome 48.43 
  45,397,229 45,397,229 Chromosome 19 48.13 
  45,397,229 45,397,229 Band 19q13.32 44.85 
logLRw = log likelihood ratio for the window 
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Table 4.7. Optimized windows for top 10 genes with a large scan-statistic in risk and protective effects 
Chr 
Optimized window 
Gene logLRw 
Optimized window 
p-value a 
No. of 
subjects 
No. of 
variants in 
the window Start End SKAT Burden 
Risk effect        
 11 1,018,274 1,018,379 MUC6 56.19 1.16×10-16 9.05×10-17 9,664 4 
 19 17,566,477 17,566,489 NXNL1 45.88 7.39×10-7 7.20×10-7 7,679 4 
 6 41,126,655 41,129,252 TREM2 31.19 2.55×10-11 7.22×10-14 9,801 8 
 7 149,482,580 149,520,553 SSPO 21.19 0.18 0.30 2,369 137 
 4 190,903,822 190,903,880 TUBB4Q b 18.59 0.045 0.072 9,175 9 
 17 18,907,029 18,923,180 SLC5A10 17.21 5.18×10-4 4.51×10-4 9,829 8 
 14 74,763,064 74,766,360 ABCD4 16.16 8.48×10-3 8.48×10-3 10,029 4 
 7 122,303,575 122,303,598 CADPS2 16.09 1.93×10-7 1.11×10-7 9,825 2 
 15 41,862,356 41,862,520 TYRO3 14.48 8.12×10-10 1.81×10-8 8,243 3 
 11 10,327,875 10,327,875 ADM 13.68 3.10×10-8 c - 9,020 1 
          
Protective effect        
 11 1,016,800 1,017,015 MUC6 51.62 1.14×10-12 2.00×10-10 6,933 9 
 19 45,397,229 45,397,229 TOMM40 48.43 2.12×10-21 c - 7,978 1 
 19 45,312,432 45,316,606 BCAM 34.95 1.89×10-8 1.00×10-8 8,909 9 
 19 45,296,767 45,297,479 CBLC 24.83 2.66×10-5 4.47×10-6 9,457 6 
 11 55,594,868 55,595,291 OR5L2 22.98 1.98×10-4 9.39×10-5 9,655 7 
 2 89,246,948 89,246,978 IGKV1-5 16.31 2.19×10-3 1.02×10-3 9,561 4 
 19 55,179,184 55,179,217 LILRB4 16.29 6.38×10-5 2.65×10-5 9,774 3 
 6 30,954,438 30,955,218 MUC21 15.71 0.11 0.17 6,702 55 
 3 100,170,589 100,170,628 LNP1 14.92 2.11×10-7 1.02×10-6 7,798 2 
 14 50,799,018 50,857,010 CDKL1 14.61 1.71×10-4 9.19×10-3 7,995 15 
a P-values obtained from the subjects with no missing variants; b Pseudogene; c P-values were calculated by Fisher’s exact test 
logLRw = log likelihood ratio for the window; SKAT = sequence-kernel association test; Burden = the burden test  
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Table 4.8. Single-variant-based association within the optimized windows  
SNV ID Position Alleles a 
MAF (%) 
 
No. of subjects 
with minor allele OR P-value b Variant 
Cases Controls 
 
Cases Controls 
Risk effect          
 11: 1,018,274 - 1,018,379 (MUC6)         
  rs79073076 1,018,274 G/C 0.04 0.01  4 1 3.81 0.38 T1509T 
  rs200240449 1,018,334 C/T 0.27 0.19  27 19 1.35 0.38 T1489T 
  rs202193006 1,018,348 G/A 4.38 2.29  434 219 2.00 1.16×10-16 P1485S 
  rs765785447 1,018,379 G/C 3.59 1.90  359 182 1.96 1.41×10-13 A1474A 
             
 19: 17,566,477 - 17,566,489 (NXNL1)         
  rs773959663 17,566,477 G/C 1.02 0.38   88 32 2.73 4.41×10-7 G206G 
  rs761407534 17,566,481 T/C 0.93 0.33   80 28 2.84 5.46×10-7 E205G 
  rs767189869 17,566,484 T/C 0.75 0.27   71 23 2.84 6.43×10-7 E204G 
  rs750720749 17,566,489 A/C 0.86 0.28   68 23 3.10 6.58×10-6 G203G 
             
 6: 41,126,655 - 41,129,252 (TREM2)         
  rs2234256 41,126,655 A/G 0.21 0.09  22 9 2.33 0.031 L211P 
  rs2234255 41,127,543 G/A 0.11 0.01  11 1 10.48 6.50×10-3 H157Y 
  rs144250872 41,127,613 C/A 0.16 0.10  17 10 1.61 0.25 L133L 
  rs145080901 41,129,078 G/A 0.04 0.02  4 2 1.90 0.69 A105V 
  rs2234253 41,129,105 G/T 0.21 0.09  22 9 2.33 0.031 T96K 
  rs142232675 41,129,133 C/T 0.21 0.09  22 9 2.33 0.031 D87N 
  rs143332484 41,129,207 C/T 1.35 0.90  137 87 1.51 2.88×10-3 R62H 
  rs75932628 41,129,252 C/T 0.94 0.21  96 21 4.41 4.30×10-12 R47H 
A bold SNV and p-value represent the significant variants based on the false discovery rate (FDR)-adjusted significance level. 
a Major/minor alleles, b P-values were calculated by Fisher’s exact test. 
SNV= single nucleotide variant; MAF = minor allele frequency; OR = odds ratio 
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Table 4.8. (Continued) 
SNV ID Position Alleles a 
MAF (%) 
 
No. of subjects 
with minor allele OR P-value b Variant 
Cases Controls 
 
Cases Controls 
Protective effect         
 11: 1,016,800 - 1,017,015 (MUC6)         
  rs199626069 1,016,800 G/A 0.04 0.07  4 7 0.54 0.38 P2001S 
  rs761958882 1,016,801 G/C 0.03 0.06  3 6 0.48 0.33 H2000Q 
  rs756062369 1,016,809 G/T 0.04 0.07  4 7 0.54 0.38 P1998T 
  rs747778866 1,016,818 A/G 0.54 0.97  55 93 0.56 6.33×10-4 Y1995H 
  rs762086454 1,016,835 A/G 0.50 1.02  51 98 0.49 3.09×10-5 F1989S 
  rs76307106 1,016,870 G/A 0.10 0.11  10 10 0.94 1 P1977P 
  rs373231068 1,016,889 G/A 2.26 4.73  194 380 0.45 4.97×10-19 P1971L 
  rs200695483 1,016,957 T/C 0.03 0.03  3 3 0.94 1 R1948R 
  rs767697427 1,017,015 T/G 0.02 0.06  2 6 0.32 0.17 E1929A 
             
 19: 45,312,432 - 45,316,606 (BCAM)         
  rs767090237 45,312,432 G/A 0.02 0.05  2 4 0.47 0.44 L17L 
  rs573141230 45,314,496 GTGCGCT/G 0.08 0.14  8 13 0.58 0.28 R34_L35del 
  rs28399653 45,315,445 G/A 2.47 3.90  249 369 0.62 1.45×10-8 R77H 
  rs3745159 45,315,539 G/A 0.22 0.30  23 29 0.75 0.33 G108G 
  rs144124876 45,315,573 G/A 0.03 0.02  3 2 1.43 1.00 E120K 
  rs200398713 45,315,656 T/A 0.10 0.06  10 6 1.59 0.46 433+8T>A 
  rs143018179 45,315,799 C/G 0.22 0.32  23 31 0.70 0.22 A166A 
  rs28399654 45,316,588 G/A 2.45 4.02  248 383 0.60 5.75×10-10 V196I 
  rs776849980 45,316,606 G/A 0.02 0.07  2 7 0.27 0.10 601+3G>A 
A bold SNV and p-value represent the significant variants based on the false discovery rate (FDR)-adjusted significance level. 
a Major/minor alleles, b P-values were calculated by Fisher’s exact test. 
SNV= single nucleotide variant; MAF = minor allele frequency; OR = odds ratio
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Figure 4.1. Flow diagram of the subjects included in the analyses. 
 
WES = Whole-exome sequencing; ADSP = Alzheimer's Disease Sequencing Project 
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Figure 4.2. First and second principal components plots along with 1000 genome 
reference samples. Block dots indicate individuals in this study. We chose individuals 
within the red dotted circle based on Euclidean distance. 
 
AFR = African; AMR = Admixed American; EAS = East Asian; EUR = European; SAS 
= South Asian 
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Figure 4.3. Manhattan plot of scan-statistic (logLRw) for the optimized windows in each gene.  
 
 
107 
 
Supplementary Method 1 
Quality control (QC) was performed for each of the variant call formats (VCFs) received 
from two institutions; the Human Genome Sequencing Center at Baylor College of 
Medicine (hereafter, Baylor) in which genotype calling was conducted using Atlas V2 
software [181] and the Broad Institute (hereafter, Broad) in which genotype calling was 
conducted using Genome Analysis Toolkit (GATK)-HaplotypeCaller [182]. Both of the 
VCFs were derived from the same set of BAM file. 
 
Primary QC 
Distinct primary QCs were applied to each of the sets of VCFs due to differences in the 
calling pipelines. For the Broad VCFs, variants that did not have a “PASS” in the 
FILTER field were deleted. For the Baylor VCFs, variants with a low mapping score and 
genotypes that did not have a “PASS”, that had a low read depth, or that had an out-of-
range variant read to total read depth ratio were deleted. Then, monomorphic variants, 
variants with high missing rate (≥ 20%), variants with high read depth (> 500 reads), or 
variants (only for MAF > 0.001) with Hardy-Weinberg equilibrium p-value < 5×10-6 
were deleted.  
 
Concordance check between the Baylor and Broad VCFs 
Variants were compared between the QCed VCFs. The consensus protocol was defined 
as follows. 
(1) Variants in which a different alternative allele was called between the two VCFs 
were excluded. 
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(2) All genotypes in remaining variants that were concordant between the two QCed sets 
of VCFs were included in the final consensus set. 
(3) All genotypes that were discordant between the two QCed sets of VCFs were set to 
missing. 
(4) All genotypes that were present only in the QCed Baylor VCF (but were missing in 
the QCed Broad VCF) were included in the final consensus set. 
(5) Genotypes that were present only in the QCed Broad VCF (but were missing in the 
QCed Baylor VCF) that met a GQ threshold were included in the final consensus set. 
i. The genotype quality score (GQ) threshold was set to the 0.1 percentile 
(genotype-specific) based on genome-wide comparisons of WES and GWAS 
genotypes.  
ii. Genotypes from the Broad VCF that were not present in the Baylor VCF 
were excluded if they had GQ values less than 21 for “0/0” genotypes, less 
than 85 for “0/1” genotypes or less than 36 for “1/1” genotypes. 
 
Second round of variant level QC 
After the consensus genotypes were determined, the same QC protocol as the primary QC 
was applied.  
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Supplementary Method 2 
In order to optimize a window for a genetic region of interest 𝐺 (e.g., chromosome), we 
modified the sliding window approach as follows.  
 
1. We specified a large base genetic region 𝐺 and a window of interest 𝑊 to get it to 
be optimized. 
2. A total of 𝑀 variants in 𝐺 were sorted in an ascending order based on the physical 
position. 
3. We set the 𝑗th window as 𝑤𝑗 containing 𝑚𝑗 variants (𝑚𝑗 < 𝑀). We denoted the 
physical position of the 𝑖th variant as 𝑝𝑖 with 𝑖 = 1, … , 𝑚𝑗. 
4. We then calculated forward log 𝐿𝑅𝑊𝑖𝑗
𝑓
 for each window from 𝑝1 to 𝑝𝑖 with 𝑖 =
1, … , 𝑚𝑗, and obtained arg max
𝑝𝑖
log 𝐿𝑅𝑊𝑖𝑗
𝑓
. 
5. We set the end position of window as 𝑝𝑚𝑗  and calculated backward log 𝐿𝑅𝑊𝑖𝑗
𝑏  for 
each window from 𝑝𝑖 to 𝑝𝑚𝑗  with 𝑖 = 2, … , 𝑚𝑗, and obtained arg max𝑝𝑖
log 𝐿𝑅𝑊𝑖𝑗
𝑏 . 
6. We compared between max log 𝐿𝑅𝑊𝑖𝑗
𝑓
 and max log 𝐿𝑅𝑊𝑖𝑗
𝑏 . 
If max log 𝐿𝑅𝑊𝑖𝑗
𝑓
>  max log 𝐿𝑅𝑊𝑖𝑗
𝑏 , we set log 𝐿𝑅𝑊𝑗 = max log 𝐿𝑅𝑊𝑖𝑗
𝑓
, 
otherwise, log 𝐿𝑅𝑊𝑗 = max log 𝐿𝑅𝑊𝑖𝑗
𝑏 . 
7. We compared log 𝐿𝑅𝑊𝑗−1 and log 𝐿𝑅𝑊𝑗. 
If log 𝐿𝑅𝑊𝑗 ≤ log 𝐿𝑅𝑊𝑗−1, we stopped and obtained log 𝐿𝑅𝑊𝑗 and the 
window as an optimized window so that the length 𝑊𝑗 was minimized. 
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Otherwise, we repeated 3 to 7 until we obtained the maximum value of 
log 𝐿𝑅𝑊 and its window positions. 
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Supplementary Method 3 [63, 64] 
The SKAT aggregates score test statistics assuming that regression coefficient 𝛽𝑗 for the 
𝑗th variant follows an arbitrary distribution with mean 0 and variance 𝑤𝑗
2𝜓, where 𝑤𝑗 is a 
weight that depends on MAF. The SKAT test statistic is expressed as  
𝑄𝑆 = ∑ 𝑤𝑗
2𝑆𝑗
2
𝑚
𝑗=1
= ∑ 𝑤𝑗
2
𝑚
𝑗=1
{∑ 𝑔𝑖𝑗(𝑦𝑖 − ?̂?𝑖,0)
𝑛
𝑖=1
}
2
  
where 𝑔𝑖𝑗 is a genotype of the 𝑗th variant for the 𝑖th subject (𝑔𝑖𝑗 = 0, 1, or 2), and ?̂?𝑖,0 is 
a estimated probability of the phenotype under the null logistic regression model. The test 
hypothesis 𝐻0: 𝜷 = 0 is equivalent to the hypothesis 𝐻0: 𝜓 = 0. Instead of summing up 
the square of weighted score test statistics, the burden test treats the square of the sum of 
weighed score test statistics defined as  
𝑄𝐵 = (∑ 𝑤𝑗𝑆𝑗
𝑚
𝑗=1
)
2
= {∑ 𝑤𝑗
𝑚
𝑗=1
∑ 𝑔𝑖𝑗(𝑦𝑖 − ?̂?𝑖,0)
𝑛
𝑖=1
}
2
 
The SKAT is powerful when both risk and protective variants are mixed, and when a 
small proportion of variants are causal, whereas the burden test is more powerful than 
SKAT when most of the variants are causal and have the same direction of effect [63].  
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CHAPTER FIVE 
Conclusion 
Summary 
Dementia is a complex condition caused by a number of diseases each with an interplay 
of genetic and environmental factors. With the advance of molecular genetic 
technologies, studies have been performed in search of genes influencing dementia 
susceptibility. GWAS have identified many genetic loci that contribute to dementia. 
However, most of the loci have moderate to small estimated effects, often making it 
difficult to reproduce in experimental work such as transgenic mouse models. Ideally, we 
would perform global analyses including information from DNA sequence to levels of 
proteins and metabolites, which is deemed “systems genetics” [121, 123]. Genetic data 
from GWAS can play a part of the role of systems genetics by demonstrating interactions 
among genes and between gene and gene expression by utilizing eQTL mapping. Recent 
sequencing technologies have allowed us not only to increase our resolution of genetic 
associations but also to integrate information for a multi-omics/systems genetics 
approach that includes genomics, epigenomics, transcriptomics, proteomics, 
metabolomics, and microbiomics [183, 184].  
 
Disease associated genetic variants have the potential to be a powerful anchor point for 
unidirectional flow in disease causal networks, in which the genetic variants affect 
downstream layers (i.e., the levels of transcripts, proteins and metabolites). Integrating 
omics layer data with genomic data can help to identify causal SNPs and genes/regions 
and to examine causal pathways leading to disease. The purpose of this dissertation 
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research was to identify SNPs and genes/regions that are potentially causal for dementia, 
especially focusing on HS-Aging and AD using genomic and transcript data. Genomic 
and transcript data were used to conduct three studies: (1) Gene-based association study 
of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, 
ABCC9, and KCNMB2, (2) Translating Alzheimer’s disease risk polymorphisms into 
functional candidates: a survey of IGAP genes, and (3) Identifying regions harboring 
Alzheimer’s disease related rare variants using scan- statistic-based analysis of exome 
sequencing data. The major findings from each of these studies are summarized below. 
 
In the first study, we examined the genetic associations of four candidate genes (GRN, 
TMEM106B, ABCC9, and KCNMB2) for HS-Aging pathology using the large autopsy 
dataset derived from multiple research centers. The important findings are that the 
significant gene-based association between ABCC9 and HS-Aging appeared to be driven 
by a region in which a significant haplotype-based association was found, and that the 
protective haplotype was associated with down-regulation of the ABCC9 expression in 
two independent datasets. The association between ABCC9 and other dementias has 
never been reported. That is, ABCC9 could potentially be a key gene that distinguishes 
HS-Aging from other types of dementia. 
 
The ABCC9 gene encodes a transmembrane protein, a part of an ATP-sensitive potassium 
(KATP) channel complex. KATP channels are widely expressed in various brain regions 
including hippocampus [100, 185]. This channel consists of two distinct subunits: an 
inwardly rectifying K+ channel (Kir6.x) and a regulatory sulfonylurea receptor (SURx) 
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[98]. Two alternatively spliced isoforms of SUR2 (i.e., SUR2A and SUR2B) are encoded 
by ABCC9 differing only in the last 42 C-terminal amino acid residues [100, 186, 187]. 
KATP channels are formed by the combination of Kir6.x and SURx in different tissues; 
Kir6.2/SUR1 in pancreatic β-cells and brain, Kir6.2/SUR2A in heart and skeletal muscle, 
Kir6.2/SUR2B in smooth muscle and brain, and Kir6.1/SUR2B in vascular smooth 
muscle [99, 186]. KATP channels are important for neuroprotection against brain injury. 
When the ATP levels drop due to hypoxia/ischemia, vascular smooth muscle cell KATP 
channels open to increase K+ efflux, voltage-activated calcium channels close to block 
Ca2+ entry, and in turn, vasodilatation is induced for limiting tissue damage [99, 100]. 
Given the critical roles in regulation of vascular tone, KATP channel dysfunction may be 
involved in cardiovascular-related diseases. Leverenz et al. showed that HS-Aging cases 
were more likely to have history of stroke, small vessel disease, and hypertension than 
AD cases [47]. Neltner et al. reported that brains with HS-Aging pathology tended to 
have arteriolosclerosis in multiple cortical and subcortical regions [103]. Therefore, 
cerebrovascular factors might be involved in developing HS-Aging via the KATP channel-
dependent activity [105].  
 
Chapter Three examined the SNPs whish have been reported to be associated with AD. It 
is well known that the ε4 allele of APOE is the major genetic risk factor for late onset of 
AD. There are three apoE isoforms, apoE2 (cys112, cys158), apoE3 (cys112, arg158), 
and apoE4 (arg112, arg158), determined by two SNPs rs429358 (T/C) and rs7412 (C/T), 
both of which are missense variants. These isoforms have different effects on Aβ 
metabolism. The binding ability of the apoE isoforms to Aβ follows the increasing order 
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of apoE2, apoE3 and apoE4, and thus apoE2 and apoE3 inhibit the aggregation and 
enhance the clearance of Aβ compared to apoE4 [33]. A series of genome-wide 
association studies (GWAS) have identified AD-associated SNPs in addition to the 
APOE alleles. Although GWAS have succeeded in revealing numerous susceptibility 
variants for AD, we have relatively little understanding of the functional impact of these 
loci in regards to AD pathogenesis. To understand disease development mechanisms that 
genetic variants are associated with, identifying functional genes and/or variants is an 
important challenge. 
 
In this study, the possible functional effects of the IGAP SNPs on AD were examined 
under two hypotheses: “the IGAP SNP is a proxy of a coding SNP” and “the IGAP SNP 
is a regulatory SNP”. For the first hypothesis, rs2296160 in CR1, rs9270303, rs1049092, 
and rs1049086 in HLA-DRB5, rs2405442 and rs1859788 in ZCWPW1, rs7982 in CLU, 
rs12453 and rs7232 in MS4A6A, and rs3752246 in ABCA7 may be proxies of coding 
SNPs. For the second hypothesis, rs6656401 in CR1, rs10838725 in CELF1, and 
rs8093731 in DSG2 may be regulatory SNPs affecting AD-associated gene expression. 
Investigating the functional role of the suspected and replicated SNPs associated with AD 
is an important next step to understanding the genetic contributions and the functional 
pathways linking AD developmental mechanisms. AD is a complex disease with a strong 
genetic component. However, much of the genetic contribution to AD remains 
unexplained. In future studies, more investigations are needed to investigate how RNA 
and protein levels as well as their interactions are affected by known AD-correlated 
genes. 
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Chapter Four presented rare variants associated with AD. Rare variants have become a 
focus in the recent past. Imputed rare variants are typically removed from GWAS 
analyses because of low accuracy of imputation. Recent advances in sequencing 
technologies enable to accurately genotype rare variants. Whole-exome sequencing 
(WES) and whole-genome sequencing (WGS) are ideal approaches to identify novel 
variants and genes associated with complex traits. However, traditional single-variant-
based association tests are underpowered to detect rare variant associations unless sample 
size and/or effect size is very large [62]. Instead of testing single variant individually, 
more powerful and computationally efficient approaches for aggregating the effects of 
rare variants have become a standard approach for association testing. In this study, we 
applied a scan-statistic-based approach and developed an approach to construct optimized 
windows within a gene to find meaningful clusters harboring risk or protective rare 
variants for AD based on the assumption that variants located in close proximity within a 
functional protein-coding domain play a similar role in increased or decreased disease 
susceptibility. We used TREM2 and TOMM40 as highly-replicated positive controls to 
evaluate the scan-statistic-based analysis with a sliding window and an optimized 
window approach. In addition to these positive control genes, we applied the optimized 
window approach in all genes to identify regions that harbor AD associated loci.  
 
We obtained very similar scan statistics when we specified the whole genome and 
chromosome as a large genetic region 𝐺. This may indicate that the scan statistics are 
comparable between windows in different large genetic regions if the 𝐺 is large enough. 
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Ideally, it would be the best that an optimized window covers an entire gene if the gene 
itself affects a disease and captures one single variant if only the variant within the gene 
is significant. Our optimized window approach successfully identified the gene and the 
single variant in TREM2 and TOMM40, respectively. Applying the optimized window 
approach across the genome, we identified several candidate genes exhibiting risk for AD 
and others playing a protective role using the optimized window approach. 
 
Strengths and Limitations 
A major strength of this dissertation is that we evaluated genetic associations of both 
common and rare variants with neurodegenerative diseases using several statistical 
methods. Single-variant-based association tests such as through conventional logistic and 
linear regression are powerful and useful tools to identify associated common variants 
having marginal significant effects on disease. Unlike Mendelian disease, however, 
complex disease is not explained by a single variant in a single gene. As a functional unit, 
a gene/region contains one or more significant SNPs that jointly affect a disease. 
Therefore, gene/region-based association analysis is an effective strategy to identify 
candidate genes/regions contributing to natural variation in a disease, as it combines 
signals from all SNPs within a putative gene/region. Haplotype analysis is also another 
informative approach to handle multiple SNPs. It accounts for not only heterogeneity but 
also possible statistical interactions among SNPs.  
 
There are some limitations. First, all data used in three studies come from multiple 
research centers. Since a large number of observations are required in genetic studies to 
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boost statistical power and to obtain more accurate estimates, collaborative groups 
combine the raw individual data from each study and jointly analyze the pooled data 
(referred to as mega-analysis). In mega-analysis, a concern about “heterogeneity among 
studies” of the same trait has been raised. Sources of heterogeneity among studies 
contains different study designs, trait measurements, ethnic groups, genotyping chips, and 
so on. The statistical methods applied in this dissertation did not take into account 
heterogeneity among studies. Second, dementia diagnoses vary across calendar time and 
research centers. In addition, the accuracy of clinical diagnosis of AD may be hampered 
by difficulty in differentiating AD from other type of dementia or AD mixed with other 
neuropathological conditions [16]. Third, we aggregated data from some resources that 
aid in establishing a confluence within a systems genetics framework. These datasets are 
heterogeneous and can exhibit biases from the respective study designs, analytic 
protocols, and participant pools. Last, we used WES to identify novel rare variants 
associated with AD in the third study. Although WES is a powerful approach for 
discovering mutations in coding regions, it is difficult or impossible to detect important 
elements including variants in non-coding regions, large indels and repeat expansions, 
and exon- or gene-level copy number variations. Therefore, WGS is better than WES to 
capture comprehensive genomic associations. 
 
Future Research 
There are several future research ideas suggested by these dissertation studies. First, we 
incorporated only common SNPs into the gene-based and haplotype-based analyses in the 
first study. Although we showed that the associated haplotype with HS-Aging was also 
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associated with the ABCC9 expression, it is still possible that the common SNP-
association signals come from a synthetic association, i.e., that detectable common SNPs 
reflect the net effect of multiple functional rare variants on a disease. The synthetic 
association hypothesis would suggest that confirmation studies for known SNPs should 
encompass a larger region surrounding the detected common SNP in which possible rare 
variants creating the synthetic association are contained. Second, we need to evaluate 
impacts of allele specific expression on biological function related to AD. We excluded 
monoallelically expressed genes including genes on chromosomes X and Y, and HLA- 
genes in the second study. However, allele specific expression is widely spread across the 
genome, and have important implications in the genotype-phenotype associations [188]. 
Given epigenetic association between DNA methylation in HLA-DRB5 and AD 
pathology [142], we will require more investigations for the association between allele 
specific expression of HLA-DRB5 and AD pathogenesis. Third, the scan-statistic-based 
analysis we used in the third study is performed under the important assumption that each 
risk is independent because it is based on Bernoulli model. That is, the scan-statistic-
based analysis does not take into account LD. If multiple associated variants are in LD, 
using all of them would artificially inflate the test statistic. Therefore, we need to modify 
it as considering LD structure. In addition, we could expand the scan-statistic-based 
analysis for a continuous outcome using a normal distribution model so that biomarkers 
related to AD development would be handled.  
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